

# ANTIRETROVIRAL MANAGEMENT OF INFANTS WITH *IN UTERO*, INTRAPARTUM, OR BREASTFEEDING EXPOSURE TO HIV

Updated: June 25, 2026  
Reviewed: June 25, 2026

## Panel's Recommendations

### Antiretroviral Management for Infants With Exposure to HIV During the *In Utero* and Intrapartum Periods

- All newborns with *in utero* (antepartum) or intrapartum exposure to HIV should receive one or more antiretroviral (ARV) drugs, dosed appropriately for the infant's gestational age and weight and initiated as close to the time of birth as possible, preferably within 6 hours **(AII)**.
- ARV regimen selection for infants with *in utero* or intrapartum exposure to HIV should be based on predicted risk for transmission, determined by maternal HIV RNA levels (see [Table 12](#), [Table 13](#), [Table 13.1](#), and [Figure 1](#) below) **(AII)**.
- **Infants at high risk** of HIV acquisition from *in utero* or intrapartum exposure, defined as being **perinatally exposed to viremia (maternal HIV RNA  $\geq$  50 copies/mL) in the 4 weeks prior to delivery**, should be provided a three-drug ARV regimen, administered from birth for 2–6 weeks, that serves as presumptive HIV therapy and enhanced prophylaxis. If the duration of the three-drug regimen is shorter than 6 weeks, zidovudine (ZDV) should be continued alone to complete a total of 6 weeks of prophylaxis **(AII)**.
- **Infants at low risk** of *in utero* and intrapartum HIV acquisition, defined as being **perinatally exposed to HIV RNA levels  $<$ 50 copies/mL from 20 weeks of gestation through delivery**, should receive ZDV alone for a duration of 2 weeks **(AII)**.
- **Infants not meeting criteria for high or low risk** should have ARV regimens and durations based on case-specific factors related to the level and timing of viremia during the pregnancy **(AII)** (see [Table 13](#)).
- An HIV nucleic acid test (NAT) should generally be performed at birth for all infants **(AII)** but is not necessary **for infants at low risk who are not being breastfed (BIII)**. See [Diagnosis of HIV Infection in Infants and Children](#) and [Table 3. Recommended Virologic Testing Schedules for Infants With Perinatal and Breastfeeding Exposure to HIV](#) for guidance about infant testing.

### Antiretroviral Management for Infants With Exposure to HIV During the Breastfeeding Period

- **Recommendations about extended ARV prophylaxis** are based on the current and anticipated maternal virologic status during breastfeeding (see [Table 14](#) and [Table 14.1](#) below). Ideally, plans should be made during the antepartum period; reassessment should take place both at delivery and regularly during the breastfeeding period **(AII)**.
- **For infants at low risk of HIV acquisition during breastfeeding**, some members of the Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission (the Panel) do not recommend extended ARV prophylaxis; however, other Panel members do recommend extended ARV prophylaxis with either nevirapine (NVP) or lamivudine (3TC) **(CIII)**. The Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission and the Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV (the Panels) did not reach consensus. Infants are considered at low risk of transmission during breastfeeding when (1) maternal antiretroviral therapy (ART) is being taken while breastfeeding and sustained maternal virologic suppression (HIV RNA  $<$ 50 copies/mL) was achieved for at least 3 months prior to delivery and (2) the provider and patient are confident that maternal ART adherence will be maintained during breastfeeding **(AII)**.

- For infants currently at low risk of HIV acquisition during breastfeeding but with concerns for future risk, the Panels recommend extended ARV prophylaxis with either NVP or 3TC (BIII). Maternal viral genotype, characteristics of drug administration, and parent preference should be considered when choosing the ARV for extended prophylaxis (AII).
- Extended ARV prophylaxis during breastfeeding, when used, should be continued until either 4 weeks after the last exposure to breast milk or 4 weeks after concerns about maternal virologic suppression have resolved (BIII). If extended prophylaxis with NVP is planned, it should ideally be initiated from birth, replacing ZDV as the initial prophylaxis; alternatively, extended prophylaxis with 3TC should be initiated after the completion of initial ZDV prophylaxis. Adherence support should always be provided for mothers (for their treatment) and their infants (for prophylaxis) during breastfeeding (Table 14) (AIII).

#### Recommendations for Infant Antiretroviral Management When the Infant Is Exposed to New Viremia

- Breastfeeding should be stopped temporarily or discontinued and replacement feeding initiated (see Situations to Consider Modifying or Stopping Breastfeeding in [Preventing HIV Transmission During Infant Feeding](#)) (AII). Most experts recommend permanent discontinuation of breastfeeding when HIV RNA is  $\geq 200$  copies/mL (CIII).
- An infant HIV NAT should be performed (AII) (see [Diagnosis of HIV Infection in Infants and Children](#) and [Table 3. Recommended Virologic Testing Schedules for Infants With Perinatal and Breastfeeding Exposure to HIV](#) for guidance about infant testing).
- **New viremia with HIV RNA  $\geq 200$  copies/mL:** If a maternal HIV RNA level  $\geq 200$  copies/mL (viremia) develops or there is presumed viremia (e.g., reports nonadherence to ARVs), the Panels recommend cessation of breastfeeding. If the infant had not been receiving ARV prophylaxis, then a three-drug ARV regimen should be given for 4 weeks. If the infant had been receiving ARV prophylaxis with 3TC or NVP, the decision to either continue the single-drug prophylaxis or initiate treatment with a three-drug regimen should be based on maternal viral load and other factors. Consultation with a local pediatric HIV expert or the [National Perinatal HIV Hotline \(1-888-448-8765\)](#) is recommended. (AII) (see [Table 14](#) and [Table 14.1](#)).
- **New viremia with HIV RNA  $< 200$  copies/mL:** When maternal viremia that is quantifiable but  $< 200$  copies/mL develops, some Panel members recommend the initiation of a three-drug presumptive HIV therapy, other members recommend the initiation of single-drug ARV prophylaxis (NVP or 3TC), and others recommend infant ARV management based on repeat maternal HIV RNA testing (CII). The Panels did not reach consensus on management; consultation with an expert is suggested (see [Table 14](#)).

#### Infant ARV Management When Perinatal HIV Exposure Is Related to a New Diagnosis of HIV During Breastfeeding

- Infants exposed to newly diagnosed maternal HIV infection during breastfeeding should be managed like infants at high risk of *in utero* or intrapartum HIV acquisition, with HIV NAT testing, three-drug presumptive HIV therapy for 4 weeks (see [Table 14](#)), and replacement feeding. (AII). See [Diagnosis of HIV Infection in Infants and Children](#) and [Table 3. Recommended Virologic Testing Schedules for Infants With Perinatal and Breastfeeding Exposure to HIV](#) for guidance about infant testing.

Providers with questions about ARV management of perinatal HIV exposure or exposure to HIV during breastfeeding should consult an expert in pediatric HIV infection or the [National Perinatal HIV Hotline \(1-888-448-8765\)](#), which provides free clinical consultation on all aspects of perinatal HIV, including newborn care (AIII).

**Rating of Recommendations:** A = Strong; B = Moderate; C = Optional

**Rating of Evidence:** I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion

# Risk of *In Utero* or Intrapartum HIV Transmission and Antiretroviral Management of Infants

All infants with *in utero* or intrapartum exposure to HIV should receive antiretroviral (ARV) drugs during the immediate neonatal period to reduce the risk of HIV transmission, with selection of the appropriate ARV regimen guided by the level of transmission risk. HIV transmission can occur *in utero*, intrapartum, or during breastfeeding.

This section addresses ARV management of infants with exposure to HIV-1 recommended by the Panel on the Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission (Perinatal Panel) and the Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV (Pediatric Panel), collectively referred to as “the Panels.” Information about ARV management for infants perinatally exposed to HIV-2 infection is available in [HIV-2 and Pregnancy](#).

The maternal viral load (HIV RNA level) is the most important risk factor for *in utero* and intrapartum HIV transmission to the infant. Infants are at an increased risk for HIV acquisition when antiretroviral therapy (ART) is not being taken during pregnancy and when antepartum treatment does not result in antepartum viral suppression, particularly in the 4 weeks prior to delivery, but even in the second half of pregnancy. Higher viral load correlates with higher risk of transmission. A spectrum of transmission risk depends on these and other factors, including mode of birth and health status during pregnancy and delivery. Although current assays can detect very low levels of HIV RNA, data from studies on transmission and viral load that were conducted prior to the availability of highly sensitive tests indicate that an HIV RNA level <50 copies/mL sufficiently predicts low risk of HIV transmission.<sup>1,2</sup>

## Risk of HIV Transmission *In Utero*

The risk of *in utero* HIV transmission is believed to increase with gestational age, with the highest rate of *in utero* infection occurring in the third trimester. However, methodological challenges in assessing the timing of fetal infection limit the precision of risk estimates by gestational age. A definitive diagnosis of *in utero* infection during pregnancy would require invasive sampling, carrying risk that is not ethically or medically indicated. There are case reports of HIV being identified in fetal tissue as early as 8-, 15-, and 20-weeks' gestation, but whether they represented established infection remains unclear.<sup>3-5</sup> In a study of fetal thymuses in the second trimester, polymerase chain reaction testing revealed that 2 of 100 samples had HIV-1.<sup>6</sup> For this reason, the Panels have a 20 week–gestational age as a conservative gestational age threshold below which *in utero* transmission is unlikely to occur. A modeling study using profiles of viral culture positivity and seroconversion from a cohort of 95 French infants suggests that the vast majority of *in utero* HIV infection occurs in the third trimester.<sup>7</sup> Another approach has been to examine how well ARVs initiated at different gestational ages prevent *in utero* transmission. Among 34 women in a U.K./Irish cohort who started ARVs during pregnancy, HIV transmission was more likely when ARVs were started later in pregnancy (median gestational age at initiation of 30.1 weeks, interquartile range [IQR] 27.4–32.6 weeks vs. 25.9 weeks, IQR 22.4–28.7 weeks,  $P < 0.001$ ).<sup>8</sup> Another model made estimates of relative time of *in utero* or intrapartum transmission based on timing of ARV initiation; they estimated 3% of transmissions occurred before 14 weeks' gestation, 17% from 14 to 36 weeks, 50% from 36 weeks through onset of labor, and 30% from intrapartum exposure.<sup>9</sup> In summary, *in utero* HIV transmission in the context of maternal viremia is considered rare in the first trimester, uncommon but possible in the second trimester, and most common in the third trimester.

## Risk of HIV Transmission Intrapartum (During Labor and Delivery)

The highest risk of perinatal HIV transmission is from exposure in the intrapartum period (i.e., during labor and delivery). Risk increases with the level of maternal viremia.<sup>2</sup> Recommended interventions to reduce the risk of intrapartum transmission include ART for all pregnancies, intravenous zidovudine (ZDV) during labor and delivery, and scheduled cesarean birth when there is a detectable HIV-1 viral load >1,000 copies/mL (see [Intrapartum HIV Care](#)).

## Transmission Risk Assessment by HIV RNA Levels and Antenatal Time Period

[Table 12](#) below summarizes *in utero* and intrapartum HIV transmission risk according to HIV RNA levels at three antenatal time periods for the purpose of selecting infant ARV prophylaxis. A recent meta-analysis suggests that transmission is  $\leq 0.2\%$  when maternal HIV RNA levels are maintained <50 copies/mL.<sup>10</sup> However, data estimating the increased risk conferred by maternal viremia at different time points during pregnancy are limited. A study of 4,743 mother–infant pairs in the Canadian Perinatal HIV Surveillance Program (1997–2020) found that 0.5% of infants of mothers with HIV RNA levels of 50 copies/mL to <1,000 copies/mL within 4 weeks prior to delivery acquired HIV.<sup>11</sup> The Panels consider any detectable HIV RNA over 50 copies/mL as indicative of increased risk, based on the rationale that low-level viremia could serve as marker for higher-level viremia that was not detected and that infants at any elevated risk should receive the potential benefits of robust prophylaxis or presumptive treatment.

The assessment of transmission risk is generally but not exclusively dependent on HIV RNA levels during the antepartum period. The Perinatal Panel [has specific guidance for assessing maternal HIV RNA levels during pregnancy](#), (see [Initial Evaluation and Continued Monitoring of HIV During Pregnancy](#)). However, discussion of transmission risk may not align exactly with the recommended [testing schedule](#), and clinicians must continue to utilize judgment to assess risk. For example, viremia could be presumed based on reports of poor adherence for several weeks, even without a documented test. Conversely, a missed HIV RNA test in a patient with years of virologic control may not merit concern. Incident HIV infection during pregnancy and lack of receipt of ART have been previously cited as risk factors for transmission; the current guidelines incorporate the risks of those scenarios within the framework of documented or presumed viremia.

**Table 12. Transmission Risk Assessment by HIV RNA Levels and Antenatal Time Period**

Antenatal Time Period			Transmission Risk	
HIV RNA at <20 Weeks' Gestation	HIV RNA $\geq 20$ Weeks' Gestation to 4 Weeks Prior to Delivery	HIV RNA at $\leq 4$ Weeks Prior to Delivery	<i>In Utero</i>	Intrapartum
N/A <sup>a</sup>	N/A	$\geq 50$ copies/mL <sup>b</sup>	High	High
N/A <sup>a</sup>	$\geq 50$ copies/mL <sup>b</sup>	<50 copies/mL	Low to moderate	Low

≥50 copies/mL <sup>b</sup>	<50 copies/mL	<50 copies/mL	Low	Low
<50 copies/mL	<50 copies/mL	<50 copies/mL	Low	Low

<sup>a</sup> HIV RNA levels in this time period do not change the transmission risk categorization because transmission risk is determined by viremia later in gestation.

<sup>b</sup> HIV RNA values of ≥50 copies/mL can be documented or presumed (e.g., early [acute or recent] HIV, new diagnosis of HIV, or known lapse in adherence).

## Antiretroviral Management for Infants With *In Utero* or Intrapartum Exposure to HIV

Historically, the use of ARV drugs in the newborn period was referred to as ARV prophylaxis because it primarily focused on protection against newborn acquisition of HIV. More recently, clinicians have additionally sought to consider and optimize the management of newborns at elevated risk for HIV acquisition *in utero* and initiate three-drug ARV regimens as presumptive HIV therapy. In this section, the following terms will be used:

- **ARV Prophylaxis:** The administration of ARV drugs to a newborn without HIV infection to reduce the risk of HIV acquisition.
- **Presumptive HIV Therapy:** The administration of a three-drug ARV regimen to newborns at elevated risk of HIV acquisition. Presumptive HIV therapy is intended to be early treatment for a newborn who has already acquired HIV but doesn't have documentation of infection; it also serves as enhanced ARV prophylaxis against HIV acquisition among infants at high risk but not yet infected.
- **ART:** The administration of a three-drug ARV regimen to infants and children with documented HIV infection (see [Diagnosis of HIV Infection in Infants and Children](#) and [What to Start](#) in the [Pediatric Antiretroviral Guidelines](#)).


The terms ARV prophylaxis and presumptive HIV therapy describe the potential roles of ARV drugs when the HIV status of an infant is unknown, and they often overlap in neonates at high risk. For example, a presumptive HIV therapy regimen also provides drug exposure that would serve as prophylaxis for a newborn. However, it is important to note that some two-drug and three-drug ARV regimens used historically were designed and studied as prophylaxis, including some that used doses of nevirapine (NVP) that target lower exposures than the doses used for treatment of HIV infection.

The Panels recommend initiating ARV prophylaxis or presumptive HIV therapy as soon as possible after birth, preferably within 6 hours. Although the maximum interval during which newborn ARV prophylaxis can be initiated and still be beneficial is unknown, most studies support providing ARV drugs as early as possible after delivery.<sup>12-17</sup>

The guidance summarized in this section applies to infants perinatally exposed to HIV unless otherwise noted. The algorithm in [Figure 1](#) and [Table 13](#) provide an overview of neonatal ARV management recommendations according to the risk of HIV transmission from *in utero* and intrapartum exposure based on HIV RNA levels at time points during pregnancy and other factors, such as maternal receipt of and adherence to ART. [Table 13.1](#) summarizes the recommended ARV dosing for prophylaxis or presumptive HIV therapy in newborns with *in utero* or intrapartum HIV exposure. Additional information about dose selection for newborns, including preterm infants (<37 weeks gestational age), can be found in [Appendix A: Pediatric Antiretroviral Drug Information](#) in the [Pediatric Antiretroviral Guidelines](#).

The [National Perinatal HIV Hotline](#) (1-888-448-8765) is a federally funded service that provides free clinical consultation on difficult cases to clinicians who are providing care to women with HIV during pregnancy **and to mother–infant pairs after delivery and the breastfeeding period**, and consultants can provide referrals to local or regional pediatric HIV specialists.

**Figure 1. Algorithm for Antiretroviral Management of Infants With *In Utero* or Intrapartum HIV Exposure by Risk of HIV Transmission**



<sup>a</sup> Early (acute or recent) HIV infection in pregnancy may result in a scenario where viremia occurs early in gestation but is suppressed after 20 weeks and through the remainder of pregnancy until delivery. In these situations, decision-making guided by the clinical scenario is recommended (see Table 13).

<sup>b</sup> If HIV RNA testing was not performed in the 4 weeks prior to delivery, clinical judgement, based on prior viral loads and adherence history, is recommended.

<sup>c</sup> If extended prophylaxis with NVP during breastfeeding is planned, the Panel recommends initiating NVP from birth, in place of ZDV; alternatively, 3TC may be initiated after completion of ZDV.

**Key:** 3TC = lamivudine; ARV = antiretroviral; NAT = nucleic acid test; NVP = nevirapine; PCR = polymerase chain reaction; ZDV = zidovudine

**Table 13. Antiretroviral Management for Infants With *In Utero* or Intrapartum Exposure to HIV**

Clinical Setting	Risk of Acquisition		Neonatal ARV Management <sup>a,b</sup>	Rationale
	<i>In Utero</i>	Intrapartum		
<b>High Risk of Acquisition</b>				
<p>HIV RNA ≥50 copies/mL in the 4 weeks prior to delivery</p> <p>Viremia can be documented by lab or presumed by other clinical factors (e.g., new diagnosis, ART adherence problems, reports of having stopped ART prior to delivery).</p>	High	High	<p>Presumptive HIV therapy using a three-drug regimen of ZDV and 3TC plus <b>DTG or NVP</b> (treatment dose)</p> <p>Duration is from birth for 2–6 weeks; consensus not reached by members of the Panel.<sup>c</sup></p> <p>If the duration of a three-drug regimen is &lt;6 weeks, and the birth NAT is negative, ZDV should be continued alone to complete a total of 6 weeks of prophylaxis.</p> <p>HIV NAT obtained before or immediately after starting presumptive therapy with three drugs<sup>d,e</sup></p>	<p>Viremia in the 4 weeks immediately prior to delivery confers high risk for <i>in utero</i> and intrapartum transmission.</p> <p>Plasma HIV RNA levels of 50–200 copies/mL could be expected to confer lower risk than those &gt;200 copies/mL but could also be an indicator of poor adherence and raise concern for higher levels of viremia at other times.</p>
<b>Low Risk of Acquisition</b>				
<p>HIV RNA &lt;50 copies/mL from 20 weeks' gestation through delivery</p> <p>Ideally documented by at least two consecutive tests at least 4 weeks apart with HIV RNA &lt;50 copies/mL <b>but can be based on clinical judgment of providers.</b></p>	Low	Low	ZDV for 2 weeks	<p>Sustained virologic suppression from 20 weeks' gestation is associated with extremely low risk of transmission <i>in utero</i> or intrapartum.</p> <p>Although <i>in utero</i> transmission events have been documented prior to 20 weeks, the extremely low frequency of these events does not merit the presumptive HIV therapy approach.</p>

**Table 13. Antiretroviral Management for Infants With *In Utero* or Intrapartum Exposure to HIV**

Clinical Setting	Risk of Acquisition		Neonatal ARV Management <sup>a,b</sup>	Rationale
	<i>In Utero</i>	Intrapartum		
<b>Other Clinical Scenarios</b>				
HIV RNA ≥50 copies/mL at >20 weeks' gestation, but HIV RNA <50 copies/mL in the 4 weeks prior to delivery	<b>Low to Moderate</b>	<b>Low</b>	<p><b>HIV NAT at Birth<sup>d,e</sup></b></p> <p><i>Two Options for ARV Management</i></p> <ol style="list-style-type: none"> <li>1. Presumptive HIV therapy with a three-drug regimen (composed of ARVs described above for infants at high risk). If the birth HIV NAT is negative, de-escalate the prophylaxis regimen to ZDV alone to complete ZDV prophylaxis for 2–6 weeks total.<sup>c</sup></li> </ol> <p><b>OR</b></p> <ol style="list-style-type: none"> <li>2. ZDV prophylaxis for 2–6 weeks</li> </ol>	<p>Viremia in the late second and third trimester elevates risk of <i>in utero</i> transmission (increasing risk with higher HIV RNA levels and longer duration of viremia).</p> <p><i>Option 1.</i> Some Panel members believe that the potential benefit of early treatment for an infant who acquired the infection <i>in utero</i> merits a presumptive HIV therapy approach.</p> <p><i>Option 2.</i> Other Panel members believe that the marginal potential benefit and anticipated low frequency of <i>in utero</i> infection do not merit the additional complexity of and potential toxicity of presumptive HIV therapy and favor ZDV prophylaxis only.</p> <p>All infants should receive a minimum of 2 weeks ZDV prophylaxis, but up to 6 weeks may be used when indicated based on risk assessment.</p>
Early (acute or recent) HIV at any point during pregnancy	<b>Moderate to High</b> depending on maternal HIV RNA levels and weeks' gestation	<b>High</b> if HIV RNA ≥50 copies/mL in the last 4 weeks of pregnancy	HIV NAT at birth <sup>d,e</sup> Manage infant ARVs according to the level and timing of the maternal viremia as described in the rows above (just as for an infant exposed to established infection).	Early or recent HIV diagnosed at any time during pregnancy is a unique situation because very high HIV RNA levels place infants at high risk of HIV acquisition.

**Table 13. Antiretroviral Management for Infants With *In Utero* or Intrapartum Exposure to HIV**

Clinical Setting	Risk of Acquisition		Neonatal ARV Management <sup>a,b</sup>	Rationale
	<i>In Utero</i>	Intrapartum		
				For infants perinatally exposed to known HIV infection, risk of transmission increases when viremia occurs later in pregnancy. Some Panel members would manage all cases with presumptive therapy, whereas others would only use it for viremia after 20 weeks' gestation.
Unconfirmed maternal HIV status with at least one positive HIV test at delivery or postpartum <i>or</i> Newborn has a positive HIV antibody test	<b>High/Uncertain</b>	<b>High/Uncertain</b>	HIV NAT at birth <sup>d,e</sup>  Presumptive HIV therapy with a three-drug regimen as described above for newborns with a high risk of <i>in utero</i> or intrapartum HIV acquisition  If supplemental testing confirms a negative maternal HIV status, discontinue infant ARV drugs immediately.	Supplemental maternal HIV testing and/or NAT testing of the infant is required to determine the level of risk and need to continue infant presumptive HIV therapy or initiate ART. <sup>e</sup>

<sup>a</sup> Infant ARVs should be initiated in the first 6 hours after delivery, especially for infants with a high risk of acquisition. See [Table 13.1](#) for ARV dosing.

<sup>b</sup> See [HIV-2 and Pregnancy](#) for ARV prophylaxis recommendations for infants perinatally exposed to HIV-2 mono-infection. In the event of maternal HIV-2 infection or HIV-1 and HIV-2 coinfection, the infant ARV regimen should be based on the determination of low or high risk of HIV-1 transmission as described in the above table using ARVs that are active against HIV-2. Because HIV-2 is not susceptible to NVP, DTG should be used in presumptive HIV therapy regimens for infants at high risk of HIV acquisition with exposure to HIV-2 or to both HIV-1 and HIV-2.

<sup>c</sup> The optimal duration of three-drug regimen in newborns who are at a high risk for HIV acquisition is unknown. Newborns who are at a high risk for HIV acquisition should receive the ZDV component for 6 weeks. The other two ARVs—(3TC and NVP) *or* (3TC and DTG)—may be administered for 2 to 6 weeks; the recommended duration for treatment with three ARVs varies depending on infant HIV NAT results, maternal viral load at the time of delivery, and the additional risk factors for HIV transmission. Consultation with an expert in pediatric HIV is recommended when selecting a therapy duration because this decision should be based on case-specific risk factors and interim infant HIV NAT results.

<sup>d</sup> NAT test at birth should be obtained before or immediately after starting ARVs. See [Diagnosis of HIV Infection in Infants and Children](#) for additional information about HIV testing and NATs.

<sup>e</sup> When a newborn HIV NAT is positive, infant ART should be initiated without waiting for the results of confirmatory HIV NAT testing, given the low likelihood of a false-positive HIV NAT (see [When to Initiate Antiretroviral Treatment in Children With HIV Infection](#) and [What to Start](#) in the [Pediatric Antiretroviral Guidelines](#)). However, the specimen for confirmatory HIV testing should be obtained prior to ART initiation.

### **Table 13. Antiretroviral Management for Infants With *In Utero* or Intrapartum Exposure to HIV**

**Note:** Providers with questions about ARV management of infants should consult an expert in pediatric HIV infection or the [National Perinatal HIV Hotline](https://www.hiv.gov/national-perinatal-hiv-hotline) (1-888-448-8765).

**Key:** 3TC = lamivudine; ART = antiretroviral therapy; ARV = antiretroviral; DTG = dolutegravir; NAT = nucleic acid test; NVP = nevirapine; the Panels = the Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission and the Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV; ZDV = zidovudine

**Table 13.1. Drug Dosing Recommendations for Antiretroviral Prophylaxis and Presumptive HIV Therapy in Infants With *In Utero* or Intrapartum Exposure to HIV<sup>a</sup>**

This table provides dosing for antiretroviral (ARV) prophylaxis and presumptive HIV therapy in infants with *in utero* or intrapartum exposure to HIV. Dosing for additional ARV prophylaxis during breastfeeding is provided in [Table 14.1. Antiretroviral Prophylaxis Dosing for Infants Who Are Breastfed](#).

For infants with HIV infection, recommendations for initial ARV therapy regimens and ARV dosing are available in the [Pediatric Antiretroviral Guidelines](#); see [What to Start](#) and [Appendix A. Pediatric Antiretroviral Drug Information](#).

ARV Drug	Drug Doses by Gestational Age at Birth								
<b>ZDV</b>  <b>Note:</b> For newborns who are unable to tolerate oral agents, the IV dose is 75% of the oral dose while maintaining the same dosing interval.	<b>≥35 Weeks of Gestation at Birth</b>  <i>Birth to Age ≤6 Weeks</i> <ul style="list-style-type: none"> <li>• ZDV 4 mg/kg per dose orally twice daily or alternative simplified weight-band dosing (see table below)</li> </ul> <b>Simplified Weight-Band Dosing for Newborns Aged ≥35 Weeks of Gestation From Birth to 4 Weeks</b> <table border="1" style="margin-left: 20px;"> <thead> <tr> <th style="background-color: #d9ead3;">Weight Band</th> <th style="background-color: #d9ead3;">Volume of ZDV 10 mg/mL Oral Syrup Twice Daily</th> </tr> </thead> <tbody> <tr> <td>2 kg to &lt;3 kg</td> <td>1 mL</td> </tr> <tr> <td>3 kg to &lt;4 kg</td> <td>1.5 mL</td> </tr> <tr> <td>4 kg to &lt;5 kg</td> <td>2 mL</td> </tr> </tbody> </table>	Weight Band	Volume of ZDV 10 mg/mL Oral Syrup Twice Daily	2 kg to <3 kg	1 mL	3 kg to <4 kg	1.5 mL	4 kg to <5 kg	2 mL
	Weight Band	Volume of ZDV 10 mg/mL Oral Syrup Twice Daily							
	2 kg to <3 kg	1 mL							
	3 kg to <4 kg	1.5 mL							
	4 kg to <5 kg	2 mL							
<b>≥30 Weeks to &lt;35 Weeks of Gestation at Birth</b>  <i>Birth to Age &lt;2 Weeks</i> <ul style="list-style-type: none"> <li>• ZDV 2 mg/kg per dose orally twice daily</li> </ul> <i>Age 2 Weeks to ≤6 Weeks</i> <ul style="list-style-type: none"> <li>• ZDV 3 mg/kg per dose orally twice daily</li> </ul>									
<b>&lt;30 Weeks of Gestation at Birth</b>  <i>Birth to Age &lt;4 Weeks</i> <ul style="list-style-type: none"> <li>• ZDV 2 mg/kg per dose orally twice daily</li> </ul> <i>Age 4 Weeks to ≤6 Weeks</i> <ul style="list-style-type: none"> <li>• ZDV 3 mg/kg per dose orally twice daily</li> </ul>									

**Table 13.1. Drug Dosing Recommendations for Antiretroviral Prophylaxis and Presumptive HIV Therapy in Infants With *In Utero* or Intrapartum Exposure to HIV**

ARV Drug	Drug Doses by Gestational Age at Birth
3TC	<p><b>≥32 Weeks of Gestation at Birth</b></p> <p><i>Birth to Age &lt;4 Weeks</i></p> <ul style="list-style-type: none"> <li>• 3TC 2 mg/kg per dose orally twice daily</li> </ul> <p><i>Age ≥4 Weeks to ≤6 weeks</i></p> <ul style="list-style-type: none"> <li>• 3TC 4 mg/kg per dose orally twice daily</li> </ul>
DTG <sup>b</sup>	<p><b>≥37 Weeks of Gestation at Birth and Weighing ≥2 kg</b></p> <p><i>Birth to Age &lt;2 Weeks</i></p> <ul style="list-style-type: none"> <li>• DTG 5 mg (dispersible tablet) orally <b>every other day</b> (i.e., approximately every 48 hours)</li> </ul> <p><i>Age ≥2 Weeks to &lt;4 Weeks</i></p> <ul style="list-style-type: none"> <li>• DTG 5 mg (dispersible tablet) orally once daily</li> </ul> <p><b>≥37 Weeks of Gestation at Birth and Weighing ≥2 kg to &lt;6 kg</b></p> <p><i>Age ≥4 Weeks to ≤6 Weeks</i></p> <ul style="list-style-type: none"> <li>• 5 mg once daily</li> </ul> <p><b>≥37 Weeks of Gestation at Birth and Weighing 6 kg to &lt;10 kg</b></p> <p><i>Age ≥4 Weeks to ≤6 Weeks</i></p> <ul style="list-style-type: none"> <li>• 15 mg once daily</li> </ul>
<p><b>NVP<sup>c</sup></b></p> <p><b>Note:</b> These are NVP treatment doses for a presumptive HIV therapy regimen. NVP dosing for extended ARV prophylaxis during breastfeeding is provided in <a href="#">Table 14.1</a>.</p> <p><b>Note:</b> Do not use NVP if HIV-2 infection (or HIV-2 co-infection with HIV-1) is present or suspected; see <a href="#">HIV-2 and Pregnancy</a>.</p>	<p><b>≥37 Weeks of Gestation at Birth</b></p> <p><i>Birth to Age ≤6 Weeks</i></p> <ul style="list-style-type: none"> <li>• NVP 6 mg/kg per dose orally twice daily</li> </ul> <hr/> <p><b>≥34 Weeks to &lt;37 Weeks of Gestation at Birth</b></p> <p><i>Birth to Age &lt;1 Week</i></p> <ul style="list-style-type: none"> <li>• NVP 4 mg/kg per dose orally twice daily</li> </ul> <p><i>Age ≥1 Week to ≤6 Weeks</i></p> <ul style="list-style-type: none"> <li>• NVP 6 mg/kg per dose orally twice daily</li> </ul> <hr/> <p><b>≥32 Weeks to &lt;34 Weeks of Gestation at Birth</b></p> <p><i>Birth to Age &lt;2 Weeks</i></p> <ul style="list-style-type: none"> <li>• NVP 2 mg/kg per dose orally twice daily</li> </ul> <p><i>Age ≥2 Weeks to &lt;4 Weeks</i></p> <ul style="list-style-type: none"> <li>• NVP 4 mg/kg per dose orally twice daily</li> </ul> <p><i>Age ≥4 Weeks to ≤6 Weeks</i></p> <ul style="list-style-type: none"> <li>• NVP 6 mg/kg per dose orally twice daily</li> </ul>

## Table 13.1. Drug Dosing Recommendations for Antiretroviral Prophylaxis and Presumptive HIV Therapy in Infants With *In Utero* or Intrapartum Exposure to HIV

<sup>a</sup> The optimal duration of three-drug regimens for newborns at high risk of HIV acquisition is unknown; all infants should receive the ZDV component of the three-drug regimen for 6 weeks. The other two ARVs—(3TC and NVP) or (3TC and DTG)—may be administered for 2 to 6 weeks; the recommended duration for these ARVs varies depending on infant HIV NAT results, maternal viral load at the time of delivery, and additional risk factors for HIV transmission. Consultation with an expert in pediatric HIV is recommended when selecting a therapy duration because this decision should be based on case-specific risk factors and interim infant HIV NAT results.

<sup>b</sup> Please refer to [Dolutegravir](#) in the [Pediatric ARV Guidelines](#) for additional details about DTG dosing. Raltegravir can be used as *Alternative* in cases where DTG is not available and an integrase strand transfer inhibitor (INSTI) is desired; please see [Raltegravir](#) in the [Pediatric ARV Guidelines](#) for dosing.

<sup>c</sup> This NVP dosing for infants  $\geq 32$  to  $< 37$  weeks' gestation at birth is not approved by the FDA. The recommended doses for infants  $\geq 32$  to  $< 34$  weeks' gestation at birth are based on modeling and might underestimate potential toxicity in infants of 32 to  $< 34$  weeks gestational age because the doses used to develop the model were lower than the doses now recommended. See [Nevirapine](#) in [Appendix A: Pediatric Antiretroviral Drug Information](#) in the [Pediatric Antiretroviral Guidelines](#) for additional information about dosing.

**Key:** 3TC = lamivudine; ARV = antiretroviral; DTG = dolutegravir; FDA = U.S. Food and Drug Administration; IV = intravenous; NVP = nevirapine; ZDV = zidovudine

## Recommendations for Infant Antiretroviral Drugs in Specific Clinical Situations

In this section, [Table 13](#), and [Figure 1. Antiretroviral Management Algorithm for Infants With \*In Utero\* or Intrapartum HIV Exposure by Risk of Transmission](#), the Panels present available data and recommendations for ARV management of newborns born with *in utero* and intrapartum exposure to HIV.

### Infants at High Risk of HIV Acquisition From *In Utero* or Intrapartum Exposure

The Panels recommend that all newborns at high risk for HIV acquisition from *in utero* and intrapartum exposure have an HIV nucleic acid test (NAT) at birth to determine *in utero* HIV infection status and receive **three drugs as** presumptive HIV therapy (see [Table 13](#) and [Figure 1](#)).<sup>16,18-23</sup> HIV infection newly diagnosed during pregnancy is generally associated with high HIV RNA levels that would confer an elevated high risk of transmission to the infant, especially in the case of recent (early or acute) infection (see [Table 13](#) and [Early \(Acute and Recent\) HIV Infection](#)).

### Presumptive HIV Therapy

Early, effective treatment of HIV infection in infants restricts the viral reservoir size, reduces HIV genetic variability, and modifies the immune response.<sup>24-33</sup>

Because of these potential benefits of early ART, the Panels recommend a three-drug presumptive HIV therapy regimen that aligns with the recommended ART for infants with confirmed infection at the time of birth. Dolutegravir (DTG) plus ZDV plus (lamivudine [3TC] or emtricitabine [FTC]) is recommended for full-term ( $\geq 37$  weeks' gestational age) infants weighing  $\geq 2$  kg. NVP plus ZDV plus (3TC or FTC) is recommended for all infants weighing  $< 2$  kg and for infants  $\geq 32$  weeks to  $< 37$  weeks of gestational age. Please refer to [What to Start](#) for details. Raltegravir (RAL) is now recommended only as an *Alternative* ARV because DTG was assessed as being easier to prepare and administer and as having a higher barrier to resistance; this also aligns with the Panels' general recommendations for treatment of children, for which RAL is also listed as *Alternative*.

In the event of maternal HIV-2 infection or concomitant HIV-1 and HIV-2 infection, the DTG-containing regimen should be used for presumptive therapy because HIV-2 is not susceptible to NVP.

Although no clinical trials have compared the safety and efficacy of presumptive HIV therapy with single-drug or two-drug regimens, existing data suggest that presumptive HIV therapy in neonates has not been associated with serious adverse events (see Antiretroviral Drug Safety of Infant Prophylaxis below).

At this time, the Panels do not recommend abacavir (ABC) as part of a presumptive HIV therapy regimen. However, in situations where ZDV is not available or the infant has ZDV-associated toxicity, ABC could be considered an alternative to ZDV. This substitution should be considered in circumstances where an increased risk of ZDV toxicity may exist, such as in infants with anemia or neutropenia. Negative testing for HLA-B\*5701 allele should be confirmed prior to the administration of ABC. Dosing recommendations for ABC in neonates based on the IMPAACT P1106 trial and two observational European and African cohorts are now available from the World Health Organization (WHO).<sup>34</sup> ABC is not approved by the U.S. Food and Drug Administration for use in neonates and infants aged <3 months. However, ABC is recommended by the WHO for use in full-term neonates and limited observational data suggested safety of ABC when initiated in neonates <1 month of age; see [Abacavir in the Pediatric Antiretroviral Guidelines](#) for dosing.<sup>35</sup>

The optimal duration of a three-drug regimen in newborns at high risk of HIV acquisition is unknown. Consulting an expert in pediatric HIV is recommended when selecting a therapy duration based on case-specific risk factors and interim HIV NAT results. HIV NAT diagnostic testing at birth (prior to or immediately after starting ARVs) is recommended for infants at high risk for HIV acquisition. A positive birth NAT test indicates *in utero* HIV infection. In cases where the infant's birth NAT results are negative, Panel members varied in their recommendations for the duration of presumptive HIV therapy. Some Panel members would opt to discontinue additional medications and complete 6 weeks ZDV prophylaxis alone, whereas other Panel members would continue presumptive HIV therapy for 2 to 6 weeks, depending on the risk of HIV transmission. Panel members agreed that ZDV should be continued for 6 weeks in all scenarios, regardless of the duration of the other two drugs. If the birth NAT is positive, the infant should receive an ART regimen recommended for the treatment of HIV infection (see [What to Start: Antiretroviral Treatment Regimens Recommended for Initial Therapy in Infants and Children With HIV](#) and [Appendix A: Pediatric Antiretroviral Drug Information](#) in the [Pediatric Antiretroviral Guidelines](#)).

## **Newborns at Low Risk of HIV Acquisition from *In Utero* or Intrapartum Exposure**

An infant perinatally exposed to HIV RNA levels <50 copies/mL and no HIV RNA levels ≥50 copies/mL after 20 weeks' gestation is considered to have low risk of HIV acquisition and should receive prophylaxis with ZDV alone for 2 weeks.

When ART is taken during pregnancy and labor and viral load is undetectable near or at the time of delivery, the risk of HIV acquisition in newborns is <1%.<sup>2</sup> In the Pediatric AIDS Clinical Trials Group (PACTG) 076 study, ZDV alone reduced the incidence of HIV transmission by 66%, and ZDV is recommended as prophylaxis for neonates when maternal ART resulted in consistent viral suppression during pregnancy.<sup>36</sup> Other studies have also compared NVP to ZDV infant prophylaxis.<sup>37,38</sup> The ANRS French Perinatal Cohort observed that NVP infant prophylaxis was associated with less anemia than ZDV infant prophylaxis. The optimal minimum duration of neonatal ZDV prophylaxis has not been established in clinical trials. A 6-week ZDV regimen was studied in newborns in PACTG 076.<sup>39</sup> However, evidence supporting a reduced duration of ZDV prophylaxis in infants born to mothers who were suppressed virologically during pregnancy and at the time of delivery is mounting.<sup>40-42</sup>

No studies directly compare the efficacy of a 2-week versus 4-week duration of infant ZDV prophylaxis. However, high-income countries have some experience with a 2-week duration of infant prophylaxis. The United States, as well as the United Kingdom and other European countries, recommends a 2-week neonatal ZDV prophylaxis regimen when the risk of HIV acquisition from exposure is low and/or very low, with varying criteria across countries.<sup>43,44</sup> Compared with the 6-week ZDV regimen, a 2- to 4-week ZDV regimen has been reported to allow earlier recovery from anemia in otherwise healthy newborns.<sup>45,46</sup> **Some countries recommend no infant prophylaxis in the setting of low risk for transmission.**<sup>47</sup>

## Other Clinical Scenarios

An infant perinatally exposed to **HIV RNA levels  $\geq 50$  copies/mL after 20 weeks of gestation but HIV RNA levels  $< 50$  copies/mL for the 4 weeks prior to delivery** is considered to have low-to-moderate risk for *in utero* and low risk for intrapartum acquisition of HIV (see [Table 12](#)). This assessment takes into consideration that low-level viremia could reflect intermittent adherence between laboratory tests. Low-level viremia (e.g.,  $\geq 50$  copies/mL to 200 copies/mL) is not expected to confer a high risk of *in utero* transmission of HIV but has been associated with elevated risk of subsequent virologic failure.<sup>48,49</sup> The Panels did not reach consensus on infant ARV management (see [Table 13](#)) for this clinical scenario and consider factors such as the magnitude and duration of elevated HIV RNA levels,<sup>2</sup> maternal adherence to ART, and parental input in decision-making.

Some Panel members recommend that these infants receive presumptive HIV therapy until the results of birth HIV NAT are available. If the birth HIV NAT is negative, excluding *in utero* HIV acquisition, the Panels recommend de-escalation of presumptive HIV therapy to ZDV prophylaxis to complete ZDV for a total of 6 weeks. This provides a balanced risk/benefit approach to quickly identifying *in utero* HIV acquisition, limiting exposure to presumptive HIV therapy in the event HIV transmission has not occurred *in utero*, and promptly administering very early presumptive therapy in the event of *in utero* infection. Very early ART has been shown to provide durable virologic suppression and reduce early viral reservoirs enabling HIV remission in some children with *in utero* HIV acquisition.<sup>33,50</sup> See [When to Initiate Antiretroviral Therapy in Children With HIV Infection](#) in the [Pediatric Antiretroviral Guidelines](#). However, other Panel members argue that the data supporting the potential benefit of early ART has not been demonstrated for this specific scenario, would likely apply to a small number of infants, and carries risk of avoidable toxicity to infants without *in utero* infection; for these reasons, they recommend 2 to 6 weeks of ZDV prophylaxis. Providers must decide which rationale aligns with their own assessment and should consider involving parents in the decision.

When **early (acute or recent) HIV is diagnosed during pregnancy**, infant ARVs should be managed according to the gestational timing of maternal viremia (see [Table 13](#)). Because HIV RNA levels are generally very high in these situations, some Panel members would manage all infants with a three-drug ARV regimen even with undetectable maternal viral load after 20 weeks. Other Panel members would base decisions about infant ARVs on the timing of viremia.

When there is a **new positive maternal HIV test at delivery or postpartum**, infants should receive a three-drug regimen as described above for infants at high risk of HIV acquisition. If supplemental testing confirms a negative maternal HIV status, infant ARV drugs should be discontinued immediately.

In some circumstances, the **HIV infection status of the mother is not known**; examples include a mother who refuses testing or an infant who was abandoned.<sup>51</sup> In these scenarios, testing the infant with an antibody test is recommended as a means to ascertain if the infant was born to a woman with HIV (see [Pregnancy and Postpartum HIV Testing and Identification of Perinatal and Postnatal HIV Exposure](#) in the [Pediatric Antiretroviral Guidelines](#) for additional guidance). If the infant's HIV

antibody test is positive, then the infant should be managed as an infant with high-risk HIV exposure, using a three-drug presumptive treatment regimen as described above. If the infant's HIV antibody test is negative, this could mean that the infant was not HIV exposed or that the infant had perinatal exposure to a mother experiencing acute HIV infection before seroconversion, which would be a very high-risk exposure. The choice of ARV management for infants with unknown maternal HIV status should be based on risk, using factors of the infant's history and local HIV epidemiology; discussion with a local expert or the HIV [National Perinatal HIV Hotline](https://www.hiv.gov/national-perinatal-hiv-hotline) (1-888-448-8765) is recommended.

## Newborns Exposed to Antiretroviral Drug-Resistant Virus

The optimal approach to selecting an ARV regimen for newborns exposed to ARV drug-resistant virus is unknown. Some studies have suggested that ARV drug-resistant virus may have decreased replicative capacity (reduced viral fitness) and transmissibility.<sup>52</sup> The transmission of drug-resistant virus to infants does occur.<sup>53-59</sup> Whether resistant virus increases the risk of perinatal HIV acquisition by the infant remains unclear. A secondary analysis of data from the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development–HIV Prevention Trials Network (HPTN) 040/PACTG 1043 did not find that the presence of drug-resistance mutations in mothers who had not received ARV drugs before the start of the study increased the risk of *in utero* or peripartum transmission (adjusted odds ratio 0.8; 95% confidence interval [CI], 0.4–1.5).<sup>58</sup> However, a case-control study found that resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) in the breastfeeding mother was an independent risk factor for the perinatal transmission of HIV during breastfeeding in the PROMISE trial.<sup>60</sup>

Although no trials have compared the efficacy of neonatal prophylaxis regimens customized to address maternal drug resistance, the Panels recommend considering maternal drug resistance when selecting the three-drug regimen for presumptive HIV therapy. For example, an infant at high risk of perinatal HIV infection with NNRTI resistance is likely to benefit from a three-drug regimen based on DTG rather than NVP. However, other factors must also be considered, such as gestational age and weight (limits the number of agents with available dosing) and feasibility for the caregiver to administer the regimen (e.g., dosing DTG every other day might be challenging for some parents).

Maraviroc (MVC) has been approved for infants  $\geq 2$  kg and may provide an additional ARV option for newborns perinatally exposed to multidrug-resistant HIV-1 that remains CCR5-tropic.<sup>61</sup> However, the lack of data about MVC as prophylaxis or treatment in infants and the risk of drug interactions will limit its role for routine use in neonates.

For assistance in selecting a three-drug ARV regimen for newborns perinatally exposed to known or suspected drug resistance, consultation with a pediatric HIV specialist or the [National Perinatal HIV Hotline](https://www.hiv.gov/national-perinatal-hiv-hotline) (1-888-448-8765) is recommended.

## Antiretroviral Prophylaxis for Breastfeeding Infants

HIV care should include counseling about infant feeding options (e.g., formula feeding, banked donor human milk, breastfeeding) throughout pregnancy. The conversation should include decision-making about the risk and potential benefits of ARV prophylaxis. Recommendations and dosing for infant ARV prophylaxis during breastfeeding are summarized in [Table 14](#) and [Table 14.1](#). In general, when extended ARV prophylaxis during breastfeeding is utilized, the aim is to provide continuous prophylaxis from birth. For extended ARV prophylaxis during breastfeeding, the Panels recommend either NVP or 3TC. The choice of agent should be made based on characteristics of administration

(once or twice daily), parental preference, and avoiding an agent to which the mother's virus is anticipated to be resistant (by genotype or history of treatment failure). If extended prophylaxis with NVP is planned, it should be initiated from birth (if feasible), replacing ZDV as initial postnatal prophylaxis. If extended prophylaxis with 3TC is planned, it should be initiated after the initial period of postnatal prophylaxis with ZDV; the Panels do not recommend 3TC to replace ZDV as initial prophylaxis from birth given lack of clinical data to support its efficacy as single-drug prophylaxis in that period. The duration of extended infant ARV prophylaxis can also vary based on provider and parent preference. The most conservative course is to continue prophylaxis until 4 weeks after the last exposure to breast milk. However, long-standing maternal virologic suppression may be exhibited during breastfeeding, and with provider's guidance, the decision may be made to stop prophylaxis while continuing to breastfeed. The Panels recommend patient-centered, evidence-based counseling to support shared decision-making about infant feeding. See [Preventing HIV Transmission During Infant Feeding](#) for more information on counseling, management, and monitoring.

Most data to guide decisions about infant ARV prophylaxis during breastfeeding are from studies in sub-Saharan Africa, where breastfeeding is recommended for all pregnancies impacted by HIV infection and standard practice for prophylaxis varies.<sup>62</sup> In the PROMISE study, among 1,219 infants of mothers on ART, there were seven HIV transmissions reported. Among these, five mothers had documented detectable viral loads immediately prior to the first report of the infant's positive HIV NAT; the remaining two mothers had elevated viral loads in subsequent testing.<sup>63</sup> Note that these two infants had their first detectable HIV NAT at Weeks 13 and 38 of life, beyond 6 weeks of age where infant NVP was administered according to WHO guidelines. In the Breastfeeding, Antiretrovirals, and Nutrition study, a sub-study of 31 infants with HIV and 232 infants who were uninfected and their mothers<sup>64</sup> demonstrated that there were no HIV transmissions when the mother consistently maintained a viral load less than 100 copies/mL. Bispo et al. have reported a meta-analysis of 11 studies of breastfeeding mothers with HIV who started ART before or during pregnancy and continued until at least 6 months postnatally.<sup>65</sup> This meta-analysis was limited by the heterogeneity in studies but reported an overall postnatal HIV transmission rate of 1.08% (95% CI, 0.32–1.85) at 6 months in infants who tested HIV negative at 4 to 6 weeks of age. In a *post-hoc* analysis of the HPTN 046 study, which showed 0.5% (95% CI, 0–1.4) risk of postnatal HIV transmission from mothers on ART in both the extended NVP and placebo arms, the addition of infant prophylaxis did not further reduce breastfeeding transmission in mothers who were receiving ART.<sup>66</sup>

Both NVP and 3TC have been demonstrated effective as extended prophylaxis during breastfeeding.<sup>67,68</sup> 3TC has been studied through 12 months of age and requires twice-daily administration.<sup>68</sup> NVP has been studied through 18 months of age and is given once daily.<sup>67</sup> Concerns related to the use of NVP include impaired efficacy in the context of maternal NNRTI-based ART and the development of NNRTI resistance if an infant acquires HIV while receiving NVP during breastfeeding (see Newborns Exposed to Antiretroviral Drug-Resistant Virus above).

Data suggest that infant prophylaxis can be very effective in preventing breast milk transmission in the context of maternal viremia. In the PROMISE trial, only 7 of the 1,211 (0.58%) analyzed infants in the infant NVP prophylaxis arm acquired HIV infection.<sup>63</sup> A randomized controlled trial in Burkina Faso and Zambia found that initiation of same-day 3TC prophylaxis for infants of women with a viral load of >1,000 copies/mL during breastfeeding resulted in a reduction in postnatal HIV transmission compared to local standard of care.<sup>68</sup> Although findings did not reach statistical significance because the study was underpowered, the findings suggest that early infant diagnosis, in conjunction with on-demand HIV RNA testing in the breastfeeding mother and extended infant prophylaxis, could be a valuable approach in eliminating postnatal HIV transmission risk. A pooled analysis of these trials reported that mothers with a viral load of 40 to 1,000 copies/mL in the initial 6 to 8 weeks postpartum were at high risk for having a viral load >1,000 copies/mL at 6 or 12 months postpartum.<sup>69</sup>

## Antiretroviral Prophylaxis for Breastfeeding Infants in the Setting of Sustained Virologic Suppression (HIV RNA <50 Copies/mL)

For an infant whose mother has sustained prior and anticipated future HIV RNA levels of <50 copies/mL and plans to breastfeed, one approach is to provide 2 weeks of ZDV prophylaxis, as recommended for an infant not breastfeeding. This approach is currently recommended by the British HIV Association.<sup>70</sup> However, some Panel members recommend extending the duration of ZDV prophylaxis to 4 to 6 weeks when the infant is being breastfed. Other Panel members recommend routinely extending ARV prophylaxis with NVP or 3TC during breastfeeding. *Given the lack of consensus by the Panels for a recommendation about extended ARV prophylaxis during breastfeeding, the Panels advise providers to involve the parent(s) in open discussion and shared decision-making, weighing values around risk tolerance (for transmission and toxicity) and other issues related to infant prophylaxis (e.g., prematurity).* For additional information, see Safety of Antiretroviral Drugs Used for Infant Prophylaxis below.

Maternal HIV RNA levels should be monitored more frequently during breastfeeding because viral suppression can change over time (see [Preventing HIV Transmission During Infant Feeding](#)). Decisions about infant ARV management during breastfeeding should be based on clinical assessment and incorporate shared decision-making when indicated.

Providers with questions about ARV management of infants should consult an expert in pediatric HIV infection or the [National Perinatal HIV Hotline](#) (1-888-448-8765).

**Table 14. Antiretroviral Management of Infants With Exposure to HIV During Breastfeeding**

Level of Transmission Risk During Breastfeeding by Maternal HIV RNA Levels	Description	Infant ARV Management During Breastfeeding <sup>a</sup>
Sustained Viral Suppression (HIV RNA <50 Copies/mL)	When sustained maternal virologic suppression during pregnancy (at a minimum during the third trimester has been achieved, documented by at least two HIV RNA measurements below the limits of detection at least 1 month apart) and breastfeeding and there are no concerns about adherence	<ul style="list-style-type: none"> <li>Some Panel members recommend no additional ARV prophylaxis after completion of 2-week ZDV prophylaxis for infants at low risk of <i>in utero</i> or intrapartum transmission. Others recommend extending ZDV prophylaxis to 4–6 weeks while breastfeeding. Others recommend extended prophylaxis with NVP or 3TC during breastfeeding (see <a href="#">Table 14.1</a>).</li> <li>Most Panel members recommend that, if used, extended ARV prophylaxis should be continued until 6 weeks after last exposure to breast milk. However, it may be reasonable to discontinue prophylaxis earlier when concern for maternal viremia is low.</li> </ul>

**Table 14. Antiretroviral Management of Infants With Exposure to HIV During Breastfeeding**

Level of Transmission Risk During Breastfeeding by Maternal HIV RNA Levels	Description	Infant ARV Management During Breastfeeding <sup>a</sup>
<p><b>Current HIV RNA Levels &lt;50 Copies/mL But Concerns About Future Risk</b></p>	<p>When maternal virologic suppression has been achieved during pregnancy but there is concern about future risk (e.g., ART adherence or loss of virologic suppression for other reasons) during breastfeeding</p>	<ul style="list-style-type: none"> <li>• Consider extended ARV prophylaxis with NVP or 3TC (see <a href="#">Table 14.1</a>).</li> <li>• Recommended duration is until 6 weeks after last exposure to breast milk. Providers and parents may consider cessation earlier if concerns about future risk for viremia have resolved.</li> <li>• Provide added adherence support as indicated.</li> </ul>
<p><b>New Viremia During Breastfeeding (HIV RNA ≥200 Copies/mL)</b></p>	<p>When maternal viremia with HIV RNA ≥200 copies/mL develops or presumed viremia (e.g., nonadherence, interrupted access to ARVs)</p>	<ul style="list-style-type: none"> <li>• Breastfeeding should be stopped temporarily or discontinued and replacement feeding initiated (see Situations to Consider Modifying or Stopping Breastfeeding in <a href="#">Preventing HIV Transmission During Infant Feeding</a>).</li> <li>• Perform infant HIV NAT<sup>a</sup></li> <li>• Initiate presumptive HIV therapy using three-drug regimen of ZDV, 3TC, and DTG (NVP if DTG is not available). See <a href="#">Table 14.1</a> for dosing information.</li> <li>• Duration of 4 weeks after the last breastfeeding</li> <li>• For guidance when a parent continues to breastfeed while viremic, see <a href="#">Antiretroviral Prophylaxis for Infants Exposed to Detectable HIV RNA During Breastfeeding below</a>.</li> </ul>
<p><b>New Viremia During Breastfeeding (HIV RNA &lt;200 Copies/mL)</b></p>	<p>The Panels did not reach consensus about neonatal management when maternal viremia develops that is quantifiable but &lt;200 copies/mL.</p>	<ul style="list-style-type: none"> <li>• Breastfeeding should be stopped temporarily or discontinued and replacement feeding initiated (see Situations to Consider Modifying or Stopping Breastfeeding in <a href="#">Preventing HIV Transmission During Infant Feeding</a>).</li> <li>• Perform infant HIV NAT.<sup>a</sup></li> <li>• Some Panel members recommend initiation of presumptive ARV therapy (as described for new viremia ≥200 copies/mL, above); other Panel members recommend initiation of single-drug ARV prophylaxis (see <a href="#">Table 14.1</a>).</li> </ul>

**Table 14. Antiretroviral Management of Infants With Exposure to HIV During Breastfeeding**

Level of Transmission Risk During Breastfeeding by Maternal HIV RNA Levels	Description	Infant ARV Management During Breastfeeding <sup>a</sup>
		<ul style="list-style-type: none"> <li>• Some Panel members recommend management based on repeat HIV RNA testing.</li> <li>• Consultation with an expert is suggested.</li> </ul>
<b>New Diagnosis of HIV When Breastfeeding</b>	Newly diagnosed maternal HIV while breastfeeding infant	<ul style="list-style-type: none"> <li>• Stop breastfeeding and initiate replacement feeding.</li> <li>• Perform infant HIV NAT.<sup>a</sup></li> <li>• Initiate presumptive HIV therapy using three-drug regimen of ZDV, 3TC, and DTG (NVP if DTG is not available). See <a href="#">Table 14.1</a> for dosing information.</li> <li>• Duration of 4 weeks</li> </ul>

<sup>a</sup> An HIV NAT at birth is recommended for all breastfeeding infants. A NAT should be obtained before or immediately after starting ARVs. See [Diagnosis of HIV Infection in Infants and Children](#) for additional information about infant NATs during breastfeeding and follow-up testing after maternal viremia.

**Note:** Given limited data, decisions about infant ARV prophylaxis during breastfeeding should be based on shared decision-making with the infant's parents.

**Key:** 3TC = lamivudine; ART = antiretroviral therapy; ARV = antiretroviral; DTG = dolutegravir; NAT = nucleic acid test; NVP = nevirapine; the Panels = Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission and Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV; ZDV = zidovudine

**Table 14.1. Antiretroviral Prophylaxis Dosing for Infants Who Are Breastfed**

ARV Prophylaxis for Infants When Maternal Sustained Viral Suppression Is Achieved												
Recommended Regimen	Recommended Duration and Dosing											
ZDV	ZDV administered for 2 weeks after birth (see <a href="#">Table 13.1</a> for dosing)											
Options for Extended Postnatal Prophylaxis <sup>a</sup>												
Recommended Regimen	Recommended Duration and Dosing											
NVP <sup>b,c,d</sup>	<p>NVP administered starting at birth through 6 weeks after cessation of breastfeeding</p> <p><b>Simplified Age-Based NVP Dosing for <b>Newborns</b> <b>≥36 Weeks</b> Gestation Receiving Extended NVP Prophylaxis During Breastfeeding<sup>b,c</sup></b></p> <table border="1"> <thead> <tr> <th>Age</th> <th>Dose and Volume of NVP 10 mg/mL Oral Syrup Administered Once Daily</th> </tr> </thead> <tbody> <tr> <td rowspan="2">Birth to 6 weeks</td> <td>2 kg to &lt;3 kg: 10 mg (1 mL)</td> </tr> <tr> <td>≥3 kg: 15 mg (1.5 mL)</td> </tr> <tr> <td>6 weeks to &lt;6 months</td> <td>20 mg (2 mL)</td> </tr> <tr> <td>6 months to &lt;9 months</td> <td>30 mg (3 mL)</td> </tr> <tr> <td>9 months to &lt;18 months</td> <td>40 mg (4 mL)</td> </tr> </tbody> </table>	Age	Dose and Volume of NVP 10 mg/mL Oral Syrup Administered Once Daily	Birth to 6 weeks	2 kg to <3 kg: 10 mg (1 mL)	≥3 kg: 15 mg (1.5 mL)	6 weeks to <6 months	20 mg (2 mL)	6 months to <9 months	30 mg (3 mL)	9 months to <18 months	40 mg (4 mL)
Age	Dose and Volume of NVP 10 mg/mL Oral Syrup Administered Once Daily											
Birth to 6 weeks	2 kg to <3 kg: 10 mg (1 mL)											
	≥3 kg: 15 mg (1.5 mL)											
6 weeks to <6 months	20 mg (2 mL)											
6 months to <9 months	30 mg (3 mL)											
9 months to <18 months	40 mg (4 mL)											
3TC	<p>3TC administered starting after completion of initial prophylaxis ZDV, through 6 weeks after cessation of breastfeeding</p> <p><b>Age 2 Weeks to &lt;4 Weeks</b></p> <ul style="list-style-type: none"> <li>3TC 2 mg/kg per dose orally twice daily</li> </ul> <p><b>Age ≥4 Weeks to 12 months</b></p> <ul style="list-style-type: none"> <li>Use simplified weight-band dosing outlined in the table below.</li> </ul>											

**Table 14.1. Antiretroviral Prophylaxis Dosing for Infants Who Are Breastfed**

<b>Simplified Weight-Band Dosing for 3TC (10 mg/ml Solution) When Used as Prophylaxis During Breastfeeding<sup>e</sup></b>	
<b>Weight Band</b>	<b>Dose and Volume of 3TC 10 mg/mL Oral Solution Administered Twice Daily</b>
2 kg to <3 kg	10 mg (1 mL)
3 kg to <4 kg	15 mg (1.5 mL)
4 kg to <8 kg	25 mg (2.5 mL)
≥8 kg	50 mg (5 mL)
<b>Recommended Infant ARV Management When Maternal Viremia Develops or HIV Is Diagnosed During Breastfeeding<sup>a</sup></b>	
<b>Presumptive HIV Therapy Regimens</b>	<b>Recommended Duration and Dosing</b>
<b>ZDV plus 3TC plus DTG<sup>f</sup></b>	Three-drug presumptive HIV therapy regimen. ZDV and 3TC plus NVP should be used for infants aged <4 weeks and/or weighing <3 kg. <sup>g</sup> See <a href="#">Table 13.1</a> for dosing of ZDV and 3TC in infants aged <6 weeks. Refer to drug sections in <a href="#">Appendix A: Pediatric Antiretroviral Drug Information</a> for appropriate age-based dosing of DTG and for dosing of ZDV, 3TC, NVP. Presumptive HIV therapy is recommended for a duration of 2–6 weeks (see <a href="#">Table 14</a> ).

<sup>a</sup> Consultation and referrals to local or regional Pediatric HIV specialists are available through the [National Perinatal HIV Hotline](#) (1-888-448-8765).

<sup>b</sup> NVP dosing is adapted from the [Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach](#). For infants at low risk of transmission, these doses can be given from birth. (Simplified Age-Based Dosing for Newborns ≥32 Weeks' Gestation Receiving Extended NVP Prophylaxis During Breastfeeding in the World Health Organization's [Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach](#), July 2021.)

<sup>c</sup> 3TC should be used as extended ARV prophylaxis during breastfeeding when there is evidence or concern for maternal NVP-resistant virus (including HIV-2 infection or HIV-1/HIV-2 co-infection) or when an infant cannot tolerate NVP. Dosing recommendations for 3TC are included in the table.

<sup>d</sup> For guidance on dosing NVP for infants <36 weeks gestation, please contact the [National Clinician Consultation Center](#).

<sup>e</sup> Dosing for extended 3TC prophylaxis during breastfeeding, based on established 3TC dosing for treatment and weight-band dosing used in PROMISE-EPI.

**Sources:** Menecier A, Kankasa C, et al. Optimised prevention of postnatal HIV transmission in Zambia and Burkina Faso (PROMISE-EPI): a phase 3, open-label, randomised controlled trial. *Lancet*. 2024;403(10434):1362-1371. <https://pubmed.ncbi.nlm.nih.gov/38484756>.

Nagot N, Kankasa C, Tumwine JK, et al. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial. *Lancet*. 2016;387(10018):566–573. <https://pubmed.ncbi.nlm.nih.gov/26603917/>.

## Table 14.1. Antiretroviral Prophylaxis Dosing for Infants Who Are Breastfed

<sup>f</sup> When maternal HIV infection is diagnosed while breastfeeding, a three-drug presumptive HIV therapy regimen is recommended for the infant, with a duration of 2–6 weeks (see [Table 14.1](#)). The same regimen is recommended for infants at high risk of HIV acquisition after *in utero* or intrapartum exposure (see [Table 13](#) and [Table 13.1](#)). No trials have evaluated the use of multidrug regimens to prevent transmission after cessation of breastfeeding with early (acute or recent) HIV infection. Some Panel members recommend presumptive HIV therapy until the infant's HIV status can be determined. If the infant's initial HIV NAT is negative, the optimal duration of presumptive HIV therapy is unknown. A 28-day course may be reasonable based on current recommendations for nonoccupational HIV exposure.

**Key:** 3TC = lamivudine; ARV = antiretroviral; DTG = dolutegravir; NAT = nucleic acid test; NVP = nevirapine; ZDV = zidovudine

### Antiretroviral Prophylaxis for Infants When There Is Concern About the Risk of Future Viremia During Breastfeeding

Some parents or providers may have concern about future adherence in the postpartum period or factors that may impact virologic suppression (e.g., postpartum depression, interrupted access to ARVs), even when criteria for the lowest anticipated risk of breast milk transmission are met with current and recent HIV RNA levels of <50 copies/mL.<sup>71</sup> Lapses in adherence in the postpartum period are common, with increased risk among women of younger age and more recent ART initiation.<sup>72</sup> Providers may consider additional adherence history and postpartum adherence challenges following prior pregnancies when making recommendations about infant prophylaxis during breastfeeding. There may be anticipated changes in social structure, such as moving to a new home, in the postpartum period that may generate new challenges to adherence. It is also important for providers to elicit parents' concerns, regardless of the provider's assessment. If there are concerns about ARV adherence during breastfeeding, the Panels recommend extended infant ARV prophylaxis during breastfeeding with either NVP or 3TC while also offering enhanced support of maternal adherence (see [Table 14](#) and [Table 14.1](#)). DTG is recommended as an alternative to NVP for single-drug postnatal prophylaxis during breastfeeding in the World Health Organization's 2025 [Recommendations on HIV Clinical Management](#); however, the Panels decided against recommending DTG at this time, due to limited experience during breastfeeding and the potential implications of breakthrough HIV infections developing INSTI resistance.

### Antiretroviral Prophylaxis for Infants Exposed to Detectable HIV RNA During Breastfeeding

Once breastfeeding has been initiated, parents should receive ongoing adherence support and counseling (See [Preventing HIV Transmission During Infant Feeding](#)) and be involved in decision-making about infant ARV prophylaxis and management of infant feeding. In situations where there is increased risk of postnatal transmission due to the development/occurrence of viremia during breastfeeding, the Panels advise initiation of additional infant ARV prophylaxis to prevent breastfeeding-associated HIV transmission. When detectable maternal HIV RNA levels develop during breastfeeding, the infant should be tested for HIV infection (using a NAT) prior to or immediately after initiating ARVs, as well as at specified time points after cessation of breastfeeding and completion of presumptive HIV therapy (see [Diagnosis of HIV Infection in Infants and Children](#) and [Table 3. Recommended Virologic Testing Schedule for Infants With Perinatal and Breastfeeding Exposure to HIV](#)). If infant HIV testing returns a positive HIV NAT result, see Infants with HIV Infection below and [What to Start](#) in the [Pediatric Antiretroviral Guidelines](#).

When maternal viremia is known or presumed (e.g. report of a significant lapse in adherence), the Panels recommend that breastfeeding be stopped (at least temporarily) and replacement feeding initiated (see Situations to Consider Modifying or Stopping Breastfeeding in [Preventing HIV Transmission During Infant Feeding](#)). Most experts recommend permanent discontinuation of breastfeeding when HIV RNA is  $\geq 200$  copies/mL. This guidance is more directive than the shared decision-making approach when mothers have virologic suppression. In situations where viremia is lower and an addressable cause has been identified, the added risk of short-term continued breastfeeding would be less.

## **Infant Management When There Is Maternal Viremia With HIV RNA $\geq 200$ Copies/mL While Breastfeeding**

If maternal viremia of HIV RNA level  $\geq 200$  copies/mL occurs (or is presumed from reported medication non-adherence) while breastfeeding, the Panels recommend cessation of breastfeeding and immediate initiation of infant presumptive HIV therapy using a three-drug regimen of ZDV plus 3TC plus DTG (NVP can be used when DTG is not available) (see [Table 14](#) and [Table 14.1](#) above).

If breastfeeding has been paused or stopped and the infant NAT is negative, presumptive treatment should be administered for 4 weeks after the last breastfeeding.

However, some parents may decide to continue to breastfeed despite medical guidance to stop. In this scenario, recommendations for infant ARV management will differ based on whether the infant is already receiving prophylaxis or not:

- If an infant was **not** receiving any ARV prophylaxis, three-drug presumptive HIV therapy is recommended for 4 weeks. Once the infant NAT is confirmed negative, extended prophylaxis with NVP or 3TC should be continued until 4 weeks after the last breastfeeding.
- If an infant was **already** receiving extended prophylaxis with NVP or 3TC, the decision to continue current or initiate three-drug presumptive HIV therapy should be considered based on maternal viral load; consultation with a local expert or [National Perinatal HIV Hotline](#) (1-888-448-8765) is recommended.

Continued engagement with the mother should be prioritized, reviewing ongoing risk of transmission and supporting her own adherence.

## **Management of New Maternal Viremia With HIV RNA $< 200$ Copies/mL While Breastfeeding**

In cases where new maternal viremia that is quantifiable but with HIV RNA  $< 200$  copies/mL occurs while breastfeeding, some Panel members recommend initiation of presumptive HIV therapy for the infant, other Panel members recommend initiation of single-drug ARV prophylaxis (with NVP or 3TC), and other Panel members recommend infant ARV management based on repeat maternal HIV RNA testing. The rationale for the cutoff of 200 copies/mL is that low-level viremia  $< 200$  copies/mL has been shown to predict future virologic failure with HIV RNA  $> 200$  copies/mL.<sup>73</sup> The Panels did not reach consensus about infant ARV prophylaxis or presumptive HIV therapy in this situation (see [Table 14](#)). Discussion with parents and consultation with the [National Perinatal HIV Hotline](#) (1-888-448-8765) or consultation with another expert is suggested.

## Special Situations in Breastfeeding Infants

### Infants Exposed to Newly Diagnosed Maternal HIV While Breastfeeding

When a new diagnosis of HIV in a breastfeeding woman is suspected (e.g., a positive initial screening test), breastfeeding should be discontinued immediately, until HIV infection has been excluded by supplementary testing. Pumping and temporarily discarding or freezing breast milk can be recommended when maternal HIV while breastfeeding is suspected but HIV serostatus is not yet confirmed and continuation of breastfeeding is desired. Once HIV infection has been excluded, breastfeeding can safely resume. However, given the exceptionally high risk of HIV transmission when HIV is acquired or diagnosed during breastfeeding, the Panels advise strongly against breastfeeding in this scenario and recommend replacement feeding with formula or banked pasteurized donor milk.<sup>74</sup> See New HIV Diagnosis While Breastfeeding in [Diagnosis of HIV Infection in Infants and Children](#) for guidance about infant testing.

Infants who are breastfeeding and have a mother who has been newly diagnosed with HIV during breastfeeding are considered to be at high risk of HIV acquisition and should be treated with a three-drug presumptive HIV therapy regimen for 4 weeks (see [Table 14](#) and [Table 14.1](#)). A 4-week duration aligns with current recommendations for nonoccupational HIV exposure. However, no trials have evaluated the use of multidrug regimens to prevent transmission after cessation of breastfeeding by a parent with early (acute or recent) HIV infection. An alternative approach favored by some Panel members is to offer presumptive HIV therapy until the infant's HIV status can be determined, followed by ZDV to complete a total 6 weeks. If the infant's initial HIV NAT is negative, the optimal duration of presumptive HIV therapy is unknown. The [National Perinatal HIV Hotline](#) (1-888-448-8765) can provide referrals to local or regional pediatric HIV specialists.

## Safety of Antiretroviral Drugs Used for Infant Prophylaxis

This section is intended to provide the information needed for clinical management and counseling parents on decision-making around infant prophylaxis. When used alone for prophylaxis in low-risk scenarios during the neonatal period and breastfeeding, ARVs appear highly safe. The most prominent toxicity in the neonatal period is anemia from ZDV given alone or in combination regimens; anemia occurs after 2 to 4 weeks but recovers with the cessation of treatment to levels similar to controls (see [Initial Postnatal Management of the Neonate Exposed to HIV](#)). During the breastfeeding period, 3TC has been shown to be safe through at least 41 weeks. NVP has been shown to be safe for infants from birth through 18 months of life; one trial identified cases with concerns of a hypersensitivity reaction, but larger subsequent trials did not report hypersensitivity reactions. Three-drug combinations appear safe within the durations currently recommended (i.e., 2–6 weeks).

Based on existing safety data, longitudinal laboratory monitoring for adverse events is not needed in otherwise healthy infants receiving currently recommended ARVs used for prophylaxis in the first 6 weeks of life. The American Academy of Pediatrics recommends periodic monitoring of hematologic and liver toxicity in breastfeeding infants receiving ARV prophylaxis beyond this period and for extended durations.<sup>75</sup>

## Zidovudine

ZDV was the first agent studied for prophylaxis against HIV transmission to infants and remains the standard of care for prophylaxis in low-risk situations. The major side effect from short-term (6 weeks or less) use of ZDV appears to be transient anemia.

- In the landmark PACTG 076 trial, 415 infants were randomized and received ZDV or placebo; hemoglobin levels in the ZDV arm were lower at the end of the 6-week treatment course but recovered and were equivalent between arms by 12 weeks.<sup>39</sup> No other toxicities were significantly different between arms, and no new toxicities were identified through 18 months of follow up.<sup>76</sup>
- Subsequent trials of 6-week regimens of ZDV alone did not identify other significant toxicities.<sup>22</sup>
- A 4-week ZDV regimen, compared with the 6-week ZDV regimen, has been reported to result in earlier recovery from anemia in infants who are HIV-exposed but otherwise healthy.<sup>45</sup> Severe cases of anemia can be treated with erythropoietin<sup>77</sup>; substitution of ZDV with 3TC and/or NVP<sup>37</sup> can also be considered.

## Lamivudine

3TC has been extensively studied in combination with ZDV, but data primarily from two trials support the safety of 3TC used alone as prophylaxis during breastfeeding through at least 41 weeks of life.

- The Mitra Study was an open-label single-arm prospective cohort trial in which 398 infants were treated with ZDV + 3TC from birth to 1 week of age, and then with 3TC alone for the duration of breastfeeding (maximum of 6 months) plus 2 weeks after stopping breastfeeding.<sup>78</sup> No serious adverse events were attributed to the study drug.
- In ANRS 12174, 1,273 infants were randomized at 7 days to receive either lopinavir/ritonavir (LPV/r) or 3TC through the completion of breastfeeding (median duration 41 weeks)<sup>79</sup>; there were no differences in adverse events rates between the arms.
- In ANRS 12397 PROMISE-EPI, in infants breastfed by mothers with HIV who were viremic during pregnancy, 3TC was initiated as prophylaxis at 6 weeks and 6 months, and continued through 12 months of age; the initial report noted no safety concerns, but the full results have not yet been published.<sup>80,81</sup>

## Nevirapine

Several trials support the safety of once-daily NVP in the first 6 weeks of life and through breastfeeding. Although reactions concerning hypersensitivity were reported in the Breastfeeding, Antiretrovirals, and Nutrition (BAN) trial, no cases have been identified in subsequent large trials or from clinical programs. Strong data also support the safety of twice-daily NVP used in a three-drug presumptive HIV therapy regimen.

- In the SWEN trial, infants were randomized to either single-dose (n = 1,047) or 6-week courses (n = 977) of once-daily NVP; adverse events were common overall (~40%) but without significant differences by arm.<sup>79</sup>
- In the BAN trial, 2,369 mother–infant dyads were randomized to infant prophylaxis with once-daily NVP, maternal ARV treatment, or enhanced control until the cessation of breastfeeding but no longer than 28 weeks.<sup>82</sup> A hypersensitivity reaction (rash, with or without fever) developed in 16 infants (1.9%, 10 of whom also had eosinophilia) within 4 weeks after the initiation of NVP

therapy; reactions resolved after NVP was replaced with 3TC. Hypersensitivity was the only adverse event significantly different between arms.

- In HPTN 046, 1,519 breastfeeding infants were randomized to 6 months of once-daily NVP or placebo (after 6 weeks of NVP from birth); no differences in adverse event rates were noted by arm through 12 months of follow up.<sup>79</sup>
- In the PEPI-Malawi trial, 3,016 infants were randomized to receive NVP with 1 week of ZDV (control), once daily NVP extended through 14 weeks, or NVP + ZDV extended through 14 weeks.<sup>83</sup> Among the three arms, no significant differences were seen in serious adverse event rates overall, nor among adverse events deemed probably associated with study drugs. However, the extended NVP + ZDV arm had significantly more serious adverse events deemed possibly related to NVP or ZDV, the most common of which was neutropenia.
- In IMPAACT 1077BF, the breastfeeding component of the PROMISE trial, 2,431 mother–infant dyads were randomized to either maternal ART or infant NVP prophylaxis (once daily) continued until 18 months after delivery or breastfeeding cessation<sup>67</sup>; the median duration of breastfeeding was 16 months in both arms. No differences were seen between study arms in Grade 3 or 4 adverse event rates or liver or skin toxicity. Of the 1,204 infants in the NVP arm who started on the study-recommended regimen, only 20 (2%) stopped the recommended regimen because of concerns of toxicity, and no cases of hypersensitivity were reported.
- The French Perinatal Cohort observed less frequent Grade 2 or higher anemia in 830 infants receiving once-daily NVP versus ZDV prophylaxis in a high-resource setting.<sup>37</sup>
- In IMPAACT P1115, infants at high risk of HIV acquisition were given NVP twice daily as part of a three-drug presumptive HIV therapy approach; NVP was dosed as 6 mg/kg twice daily for term neonates ( $\geq 37$  weeks gestational age) or 4 mg/kg twice daily for 1 week and 6 mg/kg twice daily thereafter for preterm neonates (34 to  $< 37$  weeks gestational age).<sup>23</sup> Among 438 neonates enrolled, 389 (89%) were born at term; 36 were subsequently found to have *in utero* HIV infection. Division of AIDS (DAIDS) Grade 3 or 4 adverse events that were classified as at least possibly related to ARVs were reported in 30 infants (7%; 95% CI, 5–10) but did not lead to cessation of NVP in any cases; neutropenia (25 neonates [6%]) and anemia (six neonates [1%]) were the most commonly reported toxicities.

## Abacavir

Data on the use of ABC in neonates exposed to HIV are limited but suggest it is well tolerated. In a metanalysis and population PK model that included data from three separate PK trials with a total of 45 infants aged  $< 3$  months and born to women with HIV, no adverse events of Grade 3 or greater were attributed to ABC.<sup>84</sup> At this time, the Panels suggest using ABC in neonates as an alternative to ZDV in rare situations and only after negative HLA-B\*5701 allele testing.

## Dolutegravir

Data on DTG in neonates is limited. DTG is primarily metabolized in the liver via uridine diphosphate glucuronosyltransferase family 1 member A1 (90%) with minor component cytochrome P450 3A4 (10%).<sup>85</sup> The PETITE-DTG study, a Phase 1/2 trial that evaluated the safety and pharmacokinetics of multidose DTG in neonates exposed to HIV aged 0 to 28 days, reported no adverse events related to the study drug.<sup>86</sup> In IMPAACT 2023, 18 infants received DTG every other day through Day 14 and had no Grade 3 adverse events.<sup>87</sup> Similarly, in IMPAACT 1093, which evaluated safety and pharmacokinetics in infants with HIV aged  $\geq 4$  weeks and weighing  $\geq 3$  kg no adverse events Grade 3 or higher were attributed to DTG.<sup>88</sup> Lastly, the ODYSSEY trial, an open-label, randomized, non-

inferiority trial evaluating DTG in children with HIV weighing 3 kg to <14 kg reported no adverse events related to DTG.<sup>89</sup>

## Combination ARV Regimens

Combination ARV regimens are associated with elevated risk of toxicity compared to single agents, but the three-drug regimens currently recommended for presumptive HIV therapy in neonates (e.g., NVP/ZDV/3TC or DTG/ZDV/3TC) appear very safe when used for 6 or fewer weeks. Early studies of two- and three-drug regimens used as prophylaxis suggested that hematologic and mitochondrial toxicity is more common than with exposure to a single nucleoside reverse transcriptase inhibitor (NRTI).<sup>90-94</sup> However, more recent studies provide data about the safety of the ARV regimen that is currently recommended for presumptive HIV therapy, suggesting it is generally well tolerated, but does confer an increased risk of anemia.

- In IMPAACT P1115, 438 infants of at least 34 weeks gestational age at high risk of HIV acquisition initiated NVP plus 2 NRTIs (ZDV + 3TC in 96%) within 48 hours of life and continued until *in utero* infection was excluded by HIV DNA testing at birth (a median of 13 days).<sup>23</sup> Grade 3 or 4 adverse events at least possibly related to ARVs occurred in 30 (7%) of 438 infants, with neutropenia (25 [6%]) and anemia (6 [1%]) being the most common. Toxicity led to the permanent discontinuation of ZDV in nine (2%) of 438 participants (four found to have *in utero* HIV and five without) with neutropenia and anemia being the primary reasons for discontinuation; no other ARVs were permanently discontinued because of toxicity.
- A prospective cohort study in Thailand reported a greater proportion of infants receiving ZDV/3TC/NVP for 6 weeks experienced Grade 2 anemia (38%) at 1 month compared to infants receiving ZDV alone (21%,  $P = 0.007$ ).<sup>95</sup> However, the risk of Grade 3 anemia was lower and similar between arms at 9.2% versus 10.2%, respectively ( $P = 0.81$ ). Hemoglobin levels recovered by 2 months, at which time there was no difference between the arms. No differences in neutropenia or hepatotoxicity between the groups were observed.
- A retrospective study described outcomes of 148 Canadian infants at high risk of HIV transmission treated with three drugs for 6 weeks including ARV based on NVP (40%), nelfinavir (50%), and LPV/r (5%); all together, infants receiving combination regimens had lower hemoglobin levels than infants who received ZDV alone over 6 months, but no difference was seen between the subgroup receiving NVP-based treatment compared to ZDV alone.<sup>96</sup>

## Generalizability of Available Safety Data

A number of considerations affect the generalizability of the safety data reviewed here to current patient populations.

- The majority of trials included were completed at a time when mothers of infants receiving prophylaxis were not receiving ART. It is possible that ARVs passed through breast milk could add to toxicity in infants also receiving prophylaxis during breastfeeding. Current data suggest that only clinically insignificant, small amounts of approved ARVs enter the breast milk, but this hypothetical possibility must be considered for new agents. See Safety of Antiretroviral Drugs During Breastfeeding in [Preventing HIV Transmission During Infant Feeding](#) for more details.
- This section focused on the risk of severe (Grade 3 or 4) adverse events; most trials did not report the frequencies of lower-grade toxicities. Please see the [DAIDS reference tables](#) for more information.<sup>97</sup>
- The overall rate of adverse events was high in many of the trials. For example, in IMPAACT 1077BF, approximately 35% of infants in both arms experienced Grade 3 adverse events or

death, a rate much higher than experienced in settings with more health care resources.<sup>67</sup> The high rate of events unrelated to study drugs overall may reflect the limited health care resources in the settings in sub-Saharan Africa. However, some data suggest that the normal value ranges developed in the United States may not be applicable in other settings or countries.<sup>98,99</sup> As a result, it is difficult to extrapolate the individual risk of events for an infant in settings that differ from the trials. However, the possibility of an added risk of adverse events from agents can still be evaluated by comparing arms in randomized trials.

- This section focuses on agents and approaches that are currently recommended. Safety data about approaches that are no longer recommended (e.g., NVP plus ZDV) can be found in [archived guidelines](#).
- Additional information about ARV toxicity can be found in the [Pediatric Antiretroviral Guidelines](#) (see [Appendix A: Pediatric Antiretroviral Drug Information](#)); however, data summarized there are generally from clinical trials and other studies of children with HIV, in whom the coadministration of other ARVs and comorbidities may also have contributed to toxicity.

## Infants With HIV

When infant HIV testing returns a positive HIV NAT result, the [Pediatric Antiretroviral Guidelines](#) recommend rapid initiation of ART (defined as initiating ART immediately or within days of HIV diagnosis) without waiting for a confirmatory test, given the low likelihood of a false-positive HIV NAT (see [When to Initiate Antiretroviral Treatment in Children with HIV Infection](#) and [Diagnosis of HIV Infection in Infants and Children](#)). ART should be discontinued if subsequent negative NAT testing excludes the presence of HIV infection. [What to Start](#) in the [Pediatric Antiretroviral Guidelines](#) provides recommendations about initial ART for infants and children with HIV, including those who are receiving presumptive HIV therapy or other ARV prophylaxis at the time of diagnosis.

## Knowledge Gaps

- Pharmacokinetic and safety research is urgently needed to establish safe dosing of DTG for infants born preterm. For infants <37 weeks and <2 kg, the only ARV drugs with dosing currently are NVP, 3TC, and ZDV.
- Research is needed to establish dosing and safety for long-acting ARVs for infants from birth through the end of breast feeding. Long-acting ARVs hold enormous potential to address challenges with appropriate dosing and administration of oral ARVs for prophylaxis of infants and could be a key tool in approaching elimination of transmission during breastfeeding period.
- Research is needed to (1) understand risk of HIV transmission during breastfeeding and (2) optimize maternal and infant care during this period. The risk conferred from mastitis and mixed feeding when breastfeeding mothers have virologic suppression is unknown. Furthermore, there is need for implementation research about how to optimize HIV treatment and testing of mothers and infants together, with an aim to identify and manage through periods of viremia. There is a particular need for data on transmission risk and patient management.

## References

1. Mandelbrot L, Tubiana R, Le Chenadec J, et al. No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception. *Clin Infect Dis*. 2015;61(11):1715-1725. Available at: <https://pubmed.ncbi.nlm.nih.gov/26197844>.
2. Sibide J, Le Chenadec J, Mandelbrot L, et al. Update of perinatal human immunodeficiency virus type 1 transmission in France: zero transmission for 5,482 mothers on continuous antiretroviral therapy from conception and with undetectable viral load at delivery. *Clin Infect Dis*. 2023;76(3):e590-e598. Available at: <https://pubmed.ncbi.nlm.nih.gov/36037040>.
3. Jovaisas E, Koch MA, Schafer A, et al. LAV/HTLV-III in 20-week fetus. *Lancet*. 1985;2(8464):1129. Available at: <https://pubmed.ncbi.nlm.nih.gov/2865600>.
4. Lewis SH, Reynolds-Kohler C, Fox HE, Nelson JA. HIV-1 in trophoblastic and villous Hofbauer cells, and haematological precursors in eight-week fetuses. *Lancet*. 1990;335(8689):565-568. Available at: <https://pubmed.ncbi.nlm.nih.gov/1689792>.
5. Sprecher S, Soumenkoff G, Puissant F, Degueudre M. Vertical transmission of HIV in 15-week fetus. *Lancet*. 1986;2(8501):288-289. Available at: <https://pubmed.ncbi.nlm.nih.gov/2874312>.
6. Brossard Y, Aubin JT, Mandelbrot L, et al. Frequency of early *in utero* HIV-1 infection: a blind DNA polymerase chain reaction study on 100 fetal thymuses. *AIDS*. 1995;9(4):359-366. Available at: <https://pubmed.ncbi.nlm.nih.gov/7794540>.
7. Rouzioux C, Costagliola D, Burgard M, et al. Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. The HIV Infection in Newborns French Collaborative Study Group. *Am J Epidemiol*. 1995;142(12):1330-1337. Available at: <https://pubmed.ncbi.nlm.nih.gov/7503054>.
8. Townsend CL, Cortina-Borja M, Peckham CS, et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. *AIDS*. 2008;22(8):973-981. Available at: <https://pubmed.ncbi.nlm.nih.gov/18453857>.
9. Kourtis AP, Lee FK, Abrams EJ, et al. Mother-to-child transmission of HIV-1: timing and implications for prevention. *Lancet Infect Dis*. 2006;6(11):726-732. Available at: <https://pubmed.ncbi.nlm.nih.gov/17067921>.
10. Dugdale CM, Ufio O, Giardina J, et al. Estimating the effect of maternal viral load on perinatal and postnatal HIV transmission: a systematic review and meta-analysis. *Lancet*. 2025;406(10501):349-357. Available at: <https://pubmed.ncbi.nlm.nih.gov/40652949>.
11. Brochon J, Lee T, Brophy J, et al. Postnatal prophylaxis and the use of presumptive HIV therapy for the prevention of vertical transmission of HIV in Canada 1997-2020. *J Int AIDS Soc*. 2025;28(6):e26510. Available at: <https://pubmed.ncbi.nlm.nih.gov/40462501>.
12. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. *N Engl J Med*. 1998;339(20):1409-1414. Available at: <https://pubmed.ncbi.nlm.nih.gov/9811915>.

13. Van Rompay KK, Otsyula MG, Marthas ML, et al. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. *Antimicrob Agents Chemother.* 1995;39(1):125-131. Available at: <https://pubmed.ncbi.nlm.nih.gov/7695293>.
14. Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. *Science.* 1995;270(5239):1197-1199. Available at: <https://pubmed.ncbi.nlm.nih.gov/7502044>.
15. Bottiger D, Johansson NG, Samuelsson B, et al. Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005. *AIDS.* 1997;11(2):157-162. Available at: <https://pubmed.ncbi.nlm.nih.gov/9030361>.
16. Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. *N Engl J Med.* 2012;366(25):2368-2379. Available at: <https://pubmed.ncbi.nlm.nih.gov/22716975>.
17. Dunn DT, Brandt CD, Krivine A, et al. The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. *AIDS.* 1995;9(9):F7-11. Available at: <https://pubmed.ncbi.nlm.nih.gov/8527070>.
18. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. *N Engl J Med.* 1999;341(6):385-393. Available at: <https://pubmed.ncbi.nlm.nih.gov/10432323>.
19. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. *N Engl J Med.* 1999;341(6):394-402. Available at: <https://pubmed.ncbi.nlm.nih.gov/10432324>.
20. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. *J Acquir Immune Defic Syndr.* 2002;29(5):484-494. Available at: <https://pubmed.ncbi.nlm.nih.gov/11981365>.
21. Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. *Lancet.* 2002;359(9313):1178-1186. Available at: <https://pubmed.ncbi.nlm.nih.gov/11955535>.
22. Lallemand M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) investigators. *N Engl J Med.* 2000;343(14):982-991. Available at: <https://pubmed.ncbi.nlm.nih.gov/11018164>.
23. Ruel TD, Capparelli EV, Tierney C, et al. Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study. *Lancet HIV.* 2021;8(3):e149-e157. Available at: <https://pubmed.ncbi.nlm.nih.gov/33242457>.
24. Persaud D, Ray SC, Kajdas J, et al. Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy. *AIDS Res Hum Retroviruses.* 2007;23(3):381-390. Available at: <https://pubmed.ncbi.nlm.nih.gov/17411371>.

25. Luzuriaga K, Tabak B, Garber M, et al. HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment. *J Infect Dis*. 2014;210(10):1529-1538. Available at: <https://pubmed.ncbi.nlm.nih.gov/24850788>.
26. Persaud D, Patel K, Karalius B, et al. Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents. *JAMA Pediatr*. 2014;168(12):1138-1146. Available at: <https://pubmed.ncbi.nlm.nih.gov/25286283>.
27. Rainwater-Lovett K, Ziemniak C, Watson D, et al. Paucity of intact non-induced provirus with early, long-term antiretroviral therapy of perinatal HIV infection. *PLoS One*. 2017;12(2):e0170548. Available at: <https://pubmed.ncbi.nlm.nih.gov/28178277>.
28. Rocca S, Zangari P, Cotugno N, et al. Human immunodeficiency virus (HIV)-antibody repertoire estimates reservoir size and time of antiretroviral therapy initiation in virally suppressed perinatally HIV-infected children. *J Pediatric Infect Dis Soc*. 2019;8(5):433-438. Available at: <https://pubmed.ncbi.nlm.nih.gov/30169837>.
29. Shiau S, Abrams EJ, Arpadi SM, Kuhn L. Early antiretroviral therapy in HIV-infected infants: can it lead to HIV remission? *Lancet HIV*. 2018;5(5):e250-e258. Available at: <https://pubmed.ncbi.nlm.nih.gov/29739699>.
30. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia following treatment cessation in an infant. *N Engl J Med*. 2013;369(19):1828-1835. Available at <https://pubmed.ncbi.nlm.nih.gov/24152233>.
31. Butler KM, Gavin P, Coughlan S, et al. Rapid viral rebound after 4 years of suppressive therapy in a seronegative HIV-1 infected infant treated from birth. *Pediatr Infect Dis J*. 2015;34(3):e48-e51. Available at: <https://pubmed.ncbi.nlm.nih.gov/25742088>.
32. Violari A, Cotton MF, Kuhn L, et al. A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation. *Nat Commun*. 2019;10(1):412. Available at: <https://pubmed.ncbi.nlm.nih.gov/30679439>.
33. Persaud D, Bryson Y, Nelson BS, et al. HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a Phase 1/2 proof-of-concept study. *Lancet HIV*. 2024;11(1):e20-e30. Available at: <https://pubmed.ncbi.nlm.nih.gov/38061376>.
34. World Health Organization. Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. Geneva, Switzerland. 2021. Available at: <https://www.who.int/publications/i/item/9789240022232>.
35. Bekker A, Decloedt EH, Slade G, et al. Single dose abacavir pharmacokinetics and safety in neonates exposed to human immunodeficiency virus (HIV). *Clin Infect Dis*. 2021;72(11):2032-2034. Available at: <https://pubmed.ncbi.nlm.nih.gov/32697327>.
36. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. *N Engl J Med*. 1994;331(18):1173-1180. Available at: <https://pubmed.ncbi.nlm.nih.gov/7935654>.

37. Dollfus C, Le Chenadec J, Mandelbrot L, et al. Improved hematologic outcomes in HIV1-exposed infants receiving nevirapine compared with zidovudine for postnatal prophylaxis in a high resource setting. *Pediatr Infect Dis J*. 2022;41(5):420-423. Available at: <https://pubmed.ncbi.nlm.nih.gov/35135997>.
38. Jao J, Sun S, Bonner LB, et al. Lower insulin sensitivity in newborns with *in utero* HIV and antiretroviral exposure who are uninfected in Botswana. *J Infect Dis*. 2022;226(11):2002-2009. Available at: <https://pubmed.ncbi.nlm.nih.gov/36240387>.
39. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. *N Engl J Med*. 1994;331(18):1173-1180. Available at: <https://pubmed.ncbi.nlm.nih.gov/7935654>.
40. de Ruiter A, Mercey D, Anderson J, et al. British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. *HIV Med*. 2008;9(7):452-502. Available at: <https://pubmed.ncbi.nlm.nih.gov/18840151>.
41. Ferguson W, Goode M, Walsh A, et al. Evaluation of 4 weeks' neonatal antiretroviral prophylaxis as a component of a prevention of mother-to-child transmission program in a resource-rich setting. *Pediatr Infect Dis J*. 2011;30(5):408-412. Available at: <https://pubmed.ncbi.nlm.nih.gov/21266939>.
42. Neubert J, Pfeffer M, Borkhardt A, et al. Risk adapted transmission prophylaxis to prevent vertical HIV-1 transmission: effectiveness and safety of an abbreviated regimen of postnatal oral zidovudine. *BMC Pregnancy Childbirth*. 2013;13:22. Available at: <https://pubmed.ncbi.nlm.nih.gov/23347580>.
43. British HIV Association. British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018 (2020 third interim update). 2020. Available at: <https://www.bhiva.org/file/5f1aab1ab9aba/BHIVA-Pregnancy-guidelines-2020-3rd-interim-update.pdf>.
44. Navér L, Albert J, Carlander C, et al. Prophylaxis and treatment of HIV infection in pregnancy, Swedish guidelines 2024. *Infect Dis (Lond)*. 2024;56(8):657-668. Available at: <https://pubmed.ncbi.nlm.nih.gov/38805265>.
45. Lahoz R, Noguera A, Rovira N, et al. Antiretroviral-related hematologic short-term toxicity in healthy infants: implications of the new neonatal 4-week zidovudine regimen. *Pediatr Infect Dis J*. 2010;29(4):376-379. Available at: <https://pubmed.ncbi.nlm.nih.gov/19949355>.
46. Nguyen TTT, Kobbe R, Schulze-Sturm U, et al. Reducing hematologic toxicity with short course postexposure prophylaxis with zidovudine for HIV-1 exposed infants with low transmission risk. *Pediatr Infect Dis J*. 2019;38(7):727-730. Available at: <https://pubmed.ncbi.nlm.nih.gov/31033907>.
47. Traytel A, Scherrer A, Aebi-Popp K, et al. Discontinuation of neonatal postexposure prophylaxis in infants born to HIV- infected mothers with suppressed plasma viral load: safety and implementation of the new Swiss recommendations. Presented at: 17th European AIDS Conference. 2019. Basel, Switzerland. Available at: <https://onlinelibrary.wiley.com/doi/10.1111/hiv.12814>.
48. Elvstam O, Malmborn K, Elén S, et al. Virologic failure following low-level viremia and viral blips during antiretroviral therapy: results from a European multicenter cohort. *Clin Infect Dis*. 2023;76(1):25-31. Available at: <https://pubmed.ncbi.nlm.nih.gov/36100984>.

49. Han WM, Broom J, Bopage R, et al. Investigating rates and predictors of viral blips, low-level viraemia and virological failure in the Australian HIV observational database. *Trop Med Int Health*. 2024;29(1):42-56. Available at: <https://pubmed.ncbi.nlm.nih.gov/38009461>.
50. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. *N Engl J Med*. 2013;369(19):1828-1835. Available at: <https://pubmed.ncbi.nlm.nih.gov/24152233>.
51. Cesario SK. Nurses' attitudes and knowledge of their roles in newborn abandonment. *J Perinat Educ*. 2003;12(2):31-40. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17273338>.
52. Bauer GR, Colgrove RC, Larussa PS, et al. Antiretroviral resistance in viral isolates from HIV-1-transmitting mothers and their infants. *AIDS*. 2006;20(13):1707-1712. Available at: <https://pubmed.ncbi.nlm.nih.gov/16931934>.
53. De Jose MI, Ramos JT, Alvarez S, et al. Vertical transmission of HIV-1 variants resistant to reverse transcriptase and protease inhibitors. *Arch Intern Med*. 2001;161(22):2738-2739. Available at: <https://pubmed.ncbi.nlm.nih.gov/11732941>.
54. Desai N, Mathur M. Selective transmission of multidrug resistant HIV to a newborn related to poor maternal adherence. *Sex Transm Infect*. 2003;79(5):419-421. Available at: <https://pubmed.ncbi.nlm.nih.gov/14573842>.
55. Cohan D, Feakins C, Wara D, et al. Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen. *AIDS*. 2005;19(9):989-990. Available at: <https://pubmed.ncbi.nlm.nih.gov/15905684>.
56. Fogel J, Li Q, Taha TE, et al. Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants. *Clin Infect Dis*. 2011;52(8):1069-1076. Available at: <https://pubmed.ncbi.nlm.nih.gov/21460326>.
57. Zeh C, Weidle PJ, Nafisa L, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. *PLoS Med*. 2011;8(3):e1000430. Available at: <https://pubmed.ncbi.nlm.nih.gov/21468304>.
58. Yeganeh N, Kerin T, Ank B, et al. Human immunodeficiency virus antiretroviral resistance and transmission in mother-infant pairs enrolled in a large perinatal study. *Clin Infect Dis*. 2018;66(11):1770-1777. Available at: <https://pubmed.ncbi.nlm.nih.gov/29272365>.
59. Bishop MD, Korutaro V, Boyce CL, et al. Characterizing HIV drug resistance in cases of vertical transmission in the VESTED randomized antiretroviral treatment trial. *J Acquir Immune Defic Syndr*. 2024;96(4):385-392. Available at: <https://pubmed.ncbi.nlm.nih.gov/39175843>.
60. Boyce CL, Sils T, Ko D, et al. Maternal human immunodeficiency virus (HIV) drug resistance is associated with vertical transmission and is prevalent in infected infants. *Clin Infect Dis*. 2022;74(11):2001-2009. Available at: <https://pubmed.ncbi.nlm.nih.gov/34467974>.
61. Rosebush JC, Best BM, Chadwick EG, et al. Pharmacokinetics and safety of maraviroc in neonates. *AIDS*. 2021;35(3):419-427. Available at: <https://pubmed.ncbi.nlm.nih.gov/33252481>.

62. World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. WHO Guidelines Approved by the Guidelines Review Committee. 2021. Available at: <https://pubmed.ncbi.nlm.nih.gov/34370423>. Accessed 2021.
63. Flynn PM, Taha TE, Cababasay M, et al. Association of maternal viral load and CD4 count with perinatal HIV-1 transmission risk during breastfeeding in the PROMISE postpartum component. *J Acquir Immune Defic Syndr*. 2021;88(2):206-213. Available at: <https://pubmed.ncbi.nlm.nih.gov/34108383>.
64. Davis NL, Miller WC, Hudgens MG, et al. Maternal and breastmilk viral load: impacts of adherence on peripartum HIV infections averted-the Breastfeeding, Antiretrovirals, and Nutrition Study. *J Acquir Immune Defic Syndr*. 2016;73(5):572-580. Available at: <https://pubmed.ncbi.nlm.nih.gov/27846071>.
65. Bispo S, Chikhungu L, Rollins N, et al. Postnatal HIV transmission in breastfed infants of HIV-infected women on ART: a systematic review and meta-analysis. *J Int AIDS Soc*. 2017;20(1):21251. Available at: <https://pubmed.ncbi.nlm.nih.gov/28362072>.
66. Coovadia HM, Brown ER, Fowler MG, et al. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2012;379(9812):221-228. Available at: <https://pubmed.ncbi.nlm.nih.gov/22196945>.
67. Flynn PM, Taha TE, Cababasay M, et al. Prevention of HIV-1 transmission through breastfeeding: efficacy and safety of maternal antiretroviral therapy versus infant nevirapine prophylaxis for duration of breastfeeding in HIV-1-infected women with high CD4 cell count (IMPAACT PROMISE): a randomized, open-label, clinical trial. *J Acquir Immune Defic Syndr*. 2018;77(4):383-392. Available at: <https://pubmed.ncbi.nlm.nih.gov/29239901>.
68. Kankasa C, Mennecier A, Sakana BLD, et al. Optimised prevention of postnatal HIV transmission in Zambia and Burkina Faso (PROMISE-EPI): a phase 3, open-label, randomised controlled trial. *Lancet*. 2024;403(10434):1362-1371. Available at: <https://pubmed.ncbi.nlm.nih.gov/38484756>.
69. Kania D, Moles JP, Rutagwera D, et al. Understanding vertical transmission: from molecules to populations. Presented at: Conference on Retroviruses and Opportunistic Infections. 2023. Seattle, WA. Available at: <https://www.croiconference.org/abstract/maternal-hiv-viral-load-threshold-for-guiding-extended-infant-prophylaxis-initiation>.
70. British HIV Association. BHIVA guidelines on the management of HIV in pregnancy and the postpartum period 2025. 2025. Available at: <https://bhiva.org/wp-content/uploads/2025/06/BHIVA-guidelines-on-the-management-of-HIV-in-pregnancy-and-the-postpartum-period.pdf>.
71. Momplaisir F, Hussein M, Kacanek D, et al. Perinatal depressive symptoms, human immunodeficiency virus (HIV) suppression, and the underlying role of antiretroviral therapy adherence: a longitudinal mediation analysis in the IMPAACT P1025 cohort. *Clin Infect Dis*. 2021;73(8):1379-1387. Available at: <https://pubmed.ncbi.nlm.nih.gov/33982083>.
72. Hoffman RM, Warshaw MG, Amico KR, et al. Predictors of viremia in postpartum women on antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2020;83(1):72-80. Available at: <https://pubmed.ncbi.nlm.nih.gov/31651545>.

73. Aldredge A, Mehta CC, Lahiri CD, et al. Consequences of low-level viremia among women with HIV in the United States. *AIDS*. 2024;38(13):1829-1838. Available at: <https://pubmed.ncbi.nlm.nih.gov/39110550>.
74. Van de Perre P, Lepage P, Homsy J, Dabis F. Mother-to-infant transmission of human immunodeficiency virus by breast milk: presumed innocent or presumed guilty? *Clin Infect Dis*. 1992;15(3):502-507. Available at: <https://pubmed.ncbi.nlm.nih.gov/1445596>.
75. Abuogi L, Noble L, Smith C, et al. Infant feeding for persons living with and at risk for HIV in the United States: clinical report. *Pediatrics*. 2024;153(6):e2024066843. Available at: <https://pubmed.ncbi.nlm.nih.gov/38766700>.
76. Gray GE, Urban M, Chersich MF, et al. A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. *AIDS*. 2005;19(12):1289-1297. Available at: <https://pubmed.ncbi.nlm.nih.gov/16052084>.
77. Ascensao JL, Bilgrami S, Zanjani ED. Erythropoietin. Biology and clinical applications. *Am J Pediatr Hematol Oncol*. 1991;13(4):376-387. Available at: <https://pubmed.ncbi.nlm.nih.gov/1785666>.
78. Kilewo C, Karlsson K, Massawe A, et al. Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the mitra study. *J Acquir Immune Defic Syndr*. 2008;48(3):315-323. Available at: <https://pubmed.ncbi.nlm.nih.gov/18344879>.
79. Nagot N, Kankasa C, Tumwine JK, et al. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial. *Lancet*. 2016;387(10018):566-573. Available at: <https://pubmed.ncbi.nlm.nih.gov/26603917>.
80. Menecier A, Kankasa C, Fao P, et al. Design and challenges of a large HIV prevention clinical study on mother-to-child transmission: ANRS 12397 PROMISE-EPI study in Zambia and Burkina Faso. *Contemp Clin Trials*. 2021;105:106402. Available at: <https://pubmed.ncbi.nlm.nih.gov/33872801>.
81. Kankasa C, Menecier A, Tassebedo S, et al. Improved strategy to prevent HIV postnatal transmission: a randomized trial. Presented at: Conferences of Retroviruses and Opportunistic Infections. 2023. Seattle, WA. Available at: <https://www.croiconference.org/abstract/improved-strategy-to-prevent-hiv-postnatal-transmission-a-randomized-trial>.
82. Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. *N Engl J Med*. 2010;362(24):2271-2281. Available at: <https://pubmed.ncbi.nlm.nih.gov/20554982>.
83. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. *N Engl J Med*. 2008;359(2):119-129. Available at: <https://pubmed.ncbi.nlm.nih.gov/18525035>.
84. Bekker A, Capparelli EV, Violari A, et al. Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study. *Lancet HIV*. 2022;9(1):e24-e31. Available at: <https://pubmed.ncbi.nlm.nih.gov/34883066>.

85. Chen S, St Jean P, Borland J, et al. Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics. *Pharmacogenomics*. 2014;15(1):9-16. Available at: <https://pubmed.ncbi.nlm.nih.gov/24329186>.
86. Bekker A, Salvadori N, Rabie H, et al. Safety and pharmacokinetics of dolutegravir dispersible tablets and oral films in term neonates exposed to HIV in South Africa (PETITE-DTG study): an open-label, randomised, phase 1/2 trial. *Lancet HIV*. 2025;12(11):e753-e762. Available at: <https://pubmed.ncbi.nlm.nih.gov/41075812>.
87. Momper J, Chandasana H, Wang J, et al. Pharmacokinetics and safety of chronic dolutegravir administration in neonates exposed to HIV-1 (IMPAACT 2023). Presented at: Conference on Retroviruses and Opportunistic Infections. 2025. Available at: <https://www.croiconference.org/abstract/3628-2025>.
88. Ruel TD, Acosta EP, Liu JP, et al. Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, Phase 1-2 trial. *Lancet HIV*. 2022;9(5):e332-e340. Available at: <https://pubmed.ncbi.nlm.nih.gov/35489377>.
89. Amuge P, Lugemwa A, Wynne B, et al. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. *Lancet HIV*. 2022;9(9):e638-e648. Available at: <https://pubmed.ncbi.nlm.nih.gov/36055295>.
90. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. *JAMA*. 2001;285(16):2083-2093. Available at: <https://pubmed.ncbi.nlm.nih.gov/11311097>.
91. Torres SM, Walker DM, Carter MM, et al. Mutagenicity of zidovudine, lamivudine, and abacavir following in vitro exposure of human lymphoblastoid cells or in utero exposure of CD-1 mice to single agents or drug combinations. *Environ Mol Mutagen*. 2007;48(3-4):224-238. Available at: <https://pubmed.ncbi.nlm.nih.gov/17358033>.
92. Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, et al. Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. *AIDS*. 2003;17(14):2053-2061. Available at: <https://pubmed.ncbi.nlm.nih.gov/14502008>.
93. Pacheco SE, McIntosh K, Lu M, et al. Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: an analysis of the women and infants transmission study. *J Infect Dis*. 2006;194(8):1089-1097. Available at: <https://pubmed.ncbi.nlm.nih.gov/16991083>.
94. Feiterna-Sperling C, Weizsaecker K, Bühner C, et al. Hematologic effects of maternal antiretroviral therapy and transmission prophylaxis in HIV-1-exposed uninfected newborn infants. *J Acquir Immune Defic Syndr*. 2007;45(1):43-51. Available at: <https://pubmed.ncbi.nlm.nih.gov/17356471>.
95. Anugulruengkitt S, Suntarattiwong P, Ounchanum P, et al. Safety of 6-week neonatal triple-combination antiretroviral postexposure prophylaxis in high-risk HIV-exposed infants. *Pediatr Infect Dis J*. 2019;38(10):1045-1050. Available at: <https://pubmed.ncbi.nlm.nih.gov/31365477>.

96. Lau E, Brophy J, Samson L, et al. Nevirapine pharmacokinetics and safety in neonates receiving combination antiretroviral therapy for prevention of vertical HIV transmission. *J Acquir Immune Defic Syndr.* 2017;74(5):493-498. Available at: <https://pubmed.ncbi.nlm.nih.gov/28114187>.
97. Table for grading the severity of adult and pediatric adverse events, corrected version 2.1. 2017.
98. Lubega IR, Fowler MG, Musoke PM, et al. Considerations in using US-based laboratory toxicity tables to evaluate laboratory toxicities among healthy Malawian and Ugandan infants. *J Acquir Immune Defic Syndr.* 2010;55(1):58-64. Available at: <https://pubmed.ncbi.nlm.nih.gov/20588184>.
99. Kourtis AP, Bramson B, van der Horst C, et al. Low absolute neutrophil counts in African infants. *J Int Assoc Physicians AIDS Care (Chic).* 2005;4(3):73-76. Available at: <https://pubmed.ncbi.nlm.nih.gov/16867975>.